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One of the challenges facing HIV vaccine development is the diversity of the envelope protein 
(Env).  Env only vaccines protect against homologous virus infection, but have not protected 
from heterologous virus infection. In this project, soluble Env trimers were designed and 
constructed to elicit anti-Env immune responses that recognize contemporary viral isolates. Env 
sequences isolated from the Americas, Europe, Africa, and Asia were aligned to generate a 
consensus Env sequence that represents clades A, B, C, E, and group M. These Envs were 
truncated at the transmembrane domain (Envgp140) and stabilized with a T4 fibronectin domain 
from bacteriophage. The overall hypothesis is a multi-clade vaccine expressing HIV-1 envelope 
proteins in their trimeric structure will elicit a broad cross-reactive immune response capable of 
protecting from heterologous virus challenge. Two vaccine strategies were used: a polyvalent 
vaccine strategy, using a mixture of equal amounts of consensus Env trimers of clades A, B, C 
and E (Poly consensus) in equal amounts, was directly compared to a single consensus Env 
representing the entire group M (Con M).  Initial immunogenicity studies conducted in mice 
showed consensus envelopes to be immunogenic. These studies were followed by 
immunogenicity and efficacy studies in the rhesus macaque model. The macaques were 
 v 
immunized intramuscularly three times with equal amounts of total protein of either the 
polyvalent or consensus vaccine in combination with Imject® alum. Both vaccines were 
immunogenic in monkeys and sera from vaccinated animals detected and neutralized the same 
number of envelopes from HIV-1 isolates. After challenge with the simian-human 
immunodeficiency SF162p4 virus, all polyvalent vaccinated animals were infected and two of 
the four animals vaccinated with Con M Envgp140 showed no evidence of infection.  After CD8+ 
T depletion of the two aviremic animals, virus emerged in one of those animals indicating 
potential CD8+ T cell viral control. The other animal vaccinated with Con M Envgp140 remained 
aviremic. The presence of cross-binding antibodies and low neutralizing antibodies elicited by 
two multi-clade vaccines did not provide protection to all vaccinated animals. 
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1.1 INTRODUCTION 
In 1983, Barre-Sinoussi and Gallo in parallel at two independent institutions identified the 
Human Immunodeficiency Virus (HIV) [3, 4]. The following year, HIV was established as the 
causative agent of Acquired Immunodeficiency Syndrome (AIDS). After such a monumental 
discovery, there were expectations that an effective vaccine would soon be available. 
Unfortunately this expectation has yet to become reality and HIV remains a global epidemic.  In 
2010, the World Health Organization (WHO) recorded 2.7 million new HIV infections and 34 
million individuals living with the virus worldwide [5].  
In the developing world most HIV infections occur in individuals between the ages of 25-
44 [6].  Consequently, the AIDS epidemic affects the socio-economic development of third 
world countries [7-10]. In 2000, the world’s governments identified AIDS as one of the major 
hurdles in attaining economic development[10].  AIDS has been associated with social issues 
such as increased poverty, overwhelmed health systems, decreased life expectancy, increased 
child mortality and decreased maternal health. In addition, AIDS has made it difficult to 
eradicate diseases such as malaria and tuberculosis [11-13].  The risk of a healthy individual 
acquiring TB in their lifetime is 10%, this risk increases to 50% in HIV infected patients. 
Due to HIV’s impact on global public health and the tremendous economic impact this 
virus continues to be a global threat. With its discovery ~30 years ago, many areas of research of 
HIV have evolved. These research areas include basic virology of HIV to host/pathogen 
response. One way to control infectious diseases is to design prophylactic vaccines. The work 
recorded in this dissertation aims to add to the knowledge of HIV vaccine development to move 
the field closer to the goal of a prophylactic HIV vaccine. 
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1.2 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
1.2.1 General Background 
HIV is a member of the family Retroviridae and the genus Lentivirus. Classification into the 
family retroviridae is attributable to the reverse transcriptase activity of its polymerase. Its long 
incubation period during infection, its morphology and its electron dense cylindrical inner core 
places the virus in the genus lentiviridae [14]. The structure and components of a mature HIV 
virion is illustrated in figure 1. HIV is an enveloped virus about 100 to 120 nm in diameter with 
an RNA genome approximately 10kb in length. HIV genome contains 3’ and 5’ long terminal 
repeats (LTR) and three major genes: group specific antigen (gag), polymerase (pol) and 
envelope (env) that encode for structural and enzymatic proteins. In addition to the major genes, 
the genes, tat, rev, vif, vpr, vpu, vpx, and nef (these will be discussed in detail below) are involve 
in productive infection (Figure 2). 
 After the initial discovery of HIV in 1983, a second virus with similar morphology, but 
antigenically distinct and a 55% difference in sequence homology was identified.  This virus was 
also associated with an AIDS-like illness, and was named HIV-2 [15] . The serological 
difference observed between HIV-1 and 2 was directed toward the envelope glycoprotein. The 
antibodies to Gag and Pol of HIV-2 were cross- reactive to HIV-1, but this cross reactivity was 
not seen with Env antibodies [16]. The first phylogenetic analysis of HIV was based on viruses 
isolated from Europe, North America and Africa. Initial molecular epidemiology of isolates of 
HIV-1 was based on sequencing of env and gag, more recently the analysis of the pol gene 
sequences are  used for classification [17] . This analysis led to the establishment of distinct 
subtypes. For a new viral isolate to be classified as new clade it must be sequenced from three 
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individuals with no history of relation or epidemiological relation. The diversity seen in HIV 
particularly HIV-1 is tremendous.  HIV-1 is classified into three major groups: Main (group M), 
Outliers (group O) and non-M , non O (group N) (Figure 3).   HIV-1 diversity has expanded with 
recently newly identified group P [18]. Members of the main group of HIV-1 (Group M), which 
are associated with the vast majority of infections, are further divided into clades or subtypes, A-
D, F-H and J-K.   HIV-1 group O isolates have been recovered from individuals living in African 
countries Cameroon, Gabon and Equitorial Guinea[19, 20]. In addition, isolates from different 
clades can recombine forming circulating recombinant forms (CRFs). CRFs develop as a 
consequence of a single cell being infected by genetically distinct viral strains and template 
switching between two different viral RNA during the reverse transcription reaction. Group M 
viruses are responsible for more than 95% of HIV infection worldwide. The diversity seen in the 
group of viruses is seen in the gag gene (15-20%) and env (20-30%) between clades and gag 
(3%-10%) and env (5-15%) within clades.   Within an infected person the envelope diversity has 
been reported to be up to 10%. This level of genetic diversity is one of the major challenges 
facing the development of a preventative vaccine. 
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Figure 1: Mature HIV virion.  
(image reference: David M.Knipe et. al. Fields Virology vol.2) 
The viral glycoprotein Env is present as trimeric spikes on the surface of the viral lipid envelope. The 
structural protein Gag after protoelytic cleavage give rise to the viral matrix, nucleocapsid (bound to 
the RNA genome) and the viral capsid. The viral genome, enzymatic proteins (integrase and reverse 
transcriptase), and accessory proteins are found within the capsid.  
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Figure 2: HIV Genome 
The long terminal repeats (LTR) are sites for initiation of viral RNA synthesis and required for proviral 
integration into the host cell genome. The structural and enzymatic proteins are coded by gene gag, pol and 
env. The regulatory proteins are coded by genes tat and rev, and the accessory genes coated by gene products 
vpr, vif, vpr, nef. 
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Figure 3: HIV Taxonomy  
HIV is classified into HIV-1 and HIV-2. HIV-1 is then divided into groups M, N and O. Group M is 
then divided into clades A-H, J-K. When multiple viruses infect the same cell recombination can 
occur generating recombinant viruses (CRF).  
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1.2.2 HIV Proteins 
The three major proteins of HIV are Group specific antigen (Gag), Polymerase (Pol) and 
Envelope (Env). Gag encoded by gag gene forms the structural elements of the virus. Gag 
contains p24 that encodes for the viral capsid protein, p17 that encodes the matrix protein, p6 and 
p7 that encodes nucleocapsid proteins. The numeric values given to these proteins represents the 
size at which they migrate on a denaturing protein gel. Polymerase encodes the proteins reverse 
transcriptase, intergrase and protease. Reverse transcriptase is common to all retroviruses and 
transcribes vRNA into dsDNA. Integrase integrates the viral dsDNA into the host DNA. Protease 
is needed for the cleavage of gag and pol proteins into individual proteins. Protease plays a vital 
role in virus maturation as new viral progeny bud from infected cells. Envelope encodes for the 
precursor gp160 monomer which are made up of gp120 and gp41. The gp120 is the external 
domain of the glycoprotein which interacts with the CD4 receptor and co-receptors (CCR5 and 
CXC4).  The gp41 unit of the glycoprotein functions to fuse the cell and viral membrane. The 
envelope’s functional unit is a trimer. 
HIV also contains accessory proteins involved in replication, infectivity and combating 
host immune system. Tat enhances processivity of the viral polymerase and facilitates elongation 
of vRNA. Rev regulates mRNA production. It facilitates the transport of mRNA unspliced or 
singly spliced into the cytoplasm by binding to Rev-responsive element.  During infection Nef 
reduces MHC I, CD4, CD8 expression on cell surface, affects T-cell activation, enhances virion 
infectivity, increase and decrease virus replication. Vpu affects viral release, disrupts Env-CD4 
complex, and facilitates CD4 degradation. Vif increases virus infectivity, affects virion 
assembly/or viral DNA synthesis, and is the antagonists of cellular proteins 
CEM15/APOBEC3G. Cellular proteins such as APOBEC3G evolved in primates to interfere 
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with SIV and HIV viral replication.  Vpr causes G2 arrest and facilitates entry of the pre-
integration complex into the nucleus. Vpx performs the same functions as Vpr but it is only 
found in HIV-2.  
1.2.3 HIV Envelope 
The viral envelope is responsible for viral binding and entry [21, 22]. Due to its vital role, the 
envelope is a good target for vaccine design. The monomer of the viral glycoprotein consist of a 
heavily glycosylated exterior portion referred to gp120 and the transmembrane glycoprotein 
referred to as gp41 (Figure 4). The Env forms a trimer complex on the surface of the virus.  The 
gp120 is responsible for binding the receptor and co receptor CD4 and CCR5 respectively. Based 
on sequence alignment, the gp120 unit of envelope consists of five genetically conserved and 
five genetically variable regions [23].  The gp41 transmembrane domain has of an ectodomain 
and a cytoplasmic domain.  The ectodomain consists of the N-terminal fusion peptide and the 
two heptad repeats (HR1 and HR2) which are involved in cellular and membrane fusion[23].  
This ectodomain is found beside a membrane spanning domain and cytoplasmic domain 
predicted to have to helix motifs. The gp120 and gp41 units of envelope are linked by a 
noncovalent bond. The cleavage site between the gp120 and gp41 subunits contains a furin 
cleavage site amino acid sequence Arg-Glu-Lys-Arg [24]. Besides being involved in viral entry, 
HIV Env contain epitopes that elicit immune responses that important in both vaccine 
development perspective and diagnostics. 
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Figure 4  Schematic of HIV envelope 
The Envgp160 is composed of two subunits gp120 and gp41.  The subunit gp120 includes five constant 
and five variable regions.  The gp120 is responsible for binding to HIV cellular receptors. The V3 
domain has been reported as the major determinant in co-receptor binding, with regions V1, V2, C4 
and gp41 able to modulate its tropism. The subunit gp41 is responsible for membrane fusion. 
Together these two subunits in envelope spike on the virus facilitate viral entry into susceptible cells. 
  
1.3 HIV VIRUS REPLICATION AND CLINICAL PROGRESSION AND 
TREATMENT 
1.3.1 HIV Replication 
The initial step in HIV replication is the binding of the virus envelope to its primary receptor 
CD4 (Figure 5). This initial binding results in a conformation change in envelope resulting in the 
availability of the co-receptor binding site. The human CCR5 or CXC4 are the co-receptors used 
by HIV-1.   Co- receptor binding is followed by viral and cell membrane fusion facilitated by the 
gp41 subunit of Env protein. 
Fusion of lipid bilayers allows the release of the viral capsid into the cell.  The viral RNA 
genome is reverse transcribed by the viral reverse transcriptase in the partially uncoated capsid.  
The partially double stranded DNA complex (provirus) bound by viral nucleoproteins is called 
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pre-integration complex (PIC). The PIC enters the nucleus by the viral protein vpr.  The provirus 
inserts into the host cell genome by the virally encoded integrase.  
In the infected cell, the provirus is used as a template by cellular Polymerase II (Pol II) to 
directly synthesize three major viral messenger RNA (mRNA) species. The processivity and 
efficient synthesis of viral messenger RNAs is facilitated by the viral Tat protein that interacts 
with the secondary TAR structure found in the nascent RNA.  The viral mRNA is then 
transported by the viral protein Rev from nucleous into the cell’s cytoplasm for protein 
translation. The Env protein is translated from RNA by ribosomes bound to endoplasmic 
reticulum and goes through the secretory pathway for post translation modification and 
oligomerization. The Env trimer is transported to the plasma membrane for incorporation into 
virion.  
The Gag and Gag-pol proteins and other cellular proteins are translated on free ribosomes 
in the cytoplasm.  The N-myristic acid moiety of the Gag protein allows trafficking of Gag and 
Gag-pol protein to the plasma membrane. At the plasma membrane the Gag and Gag-pol 
associate with the newly synthesized RNA genome to form a condensed capsid that buds from 
plasma membrane. As the immature virion buds from the cell, the viral protease is incorporated 
into the virion and cleaves the Gag-Pol protein to form a mature virion. 
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Figure 5: HIV replication cycle 
Infection begins with Env mediated entry through binding with receptors CD4 and CCR5. This is 
followed by membrane fusion and capsid release. Partial capsid uncoating allows for the initiation 
the RNA genome transcriptions into DNA. The viral DNA is then integrated into the host genome. 
Viral RNA is then synthesized using the integrated DNA (provirus) and cellular polymerase II. The 
RNA products are used for protein translation and incorporation into the virus. The Env is 
translated and processe through the secretory pathway and directed to the cell membrane.  The Env, 
Gag/Pol and other viral proteins are transported and assembled into immature virion cell 
membrane. After budding the virus matures due to proteolytic cleavage by the viral protease.  
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1.3.2 Brief Review of HIV/AIDS Clinical Progression  
A characteristic of HIV infection is decreased number of CD4+ T helper cells. This decrease in 
CD4+ T cells is partly due to viral infection and cell apoptosis. In figure 6, the viral loads and 
CD4+ T cell counts during the HIV/AIDS disease progression is shown. The World Health 
Organization (WHO) divided the HIV/AIDS progression into four clinical stages [25-27]. During 
the first clinical stage the patient is asymptomatic and has generalized lymphadenopathy.  This 
phase usually starts with a rapid progression in viral loads for about 3-6 weeks accompanied by a 
drop in normal CD4+ T cell levels.  Normal CD4+ T cell levels are usually between 600-1200 
cells per mm3. About 7-8 weeks after primary infection, the viremia is brought under control by 
the immune system and a viral set point is established. The established viral set points are 
dependent on each individual [28]. With the control of viremia, CD4+ T cell levels may recover 
in some individuals. 
During the second clinical stage, CD4+ T cell levels begin to decline accompanied by an 
increase in viral loads. This clinical stage is characterized by less than 10% weight loss, minor 
mucocutaneous manifestations such as Herpes Zoster and recurrent upper respiratory bacterial 
infections. Further decline of CD4+ T cells and increase of viremia is seen as patients enter 
clinical stage three. Symptoms of clinical stage three include: weight loss of more than 10%, 
unexplained chronic diarrhea and prolonged oral thrush, pulmonary TB and severe bacterial 
infections. The last clinical stage, AIDS, usually occurs ten years after primary infection. This 
phase of symptomatic disease is accompanied by CD4+ T cell counts less than 200 cells per mm3 
of blood and substantial increases in viral loads. Patients are diagnosed with HIV wasting 
syndrome, and other opportunistic infection such as Pneumocystis carinii pneumonia (PCP), 
 14 
Toxoplasmosis of the brain, herpes simplex virus infection, Kaposi sarcoma, and HIV 
encephalopathy. 
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Figure 6. CD4 and viral changes overtime in HIV/AIDS disease progression 
During the first six months of HIV infection there is an initial decline of CD4+T cells and increase in 
viral load. This phase of infection is referred to as the acute phase of infection. The acute phase of 
infection is followed by the asymptomatic phase which is characterize by the restoration of CD4 + T 
cells and  the establishment of viral set point due to control of the infection by the immune system.  
This asymptomatic phase can last for an average of 10 years until the immune system loses control of 
the viral infection. This loss of immune control is characterized by CD4+T cell decline and increase 
in viremia  eventually leads to CD4+ T cell counts less than 200 cells per mm3 and diagnosis of HIV 
wasting syndrome and opportunistic infections.    
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1.3.3 Highly Active Antiretroviral Therapy 
Two years after the discovery of the causative agent of AIDS, the first sign of possible treatment 
was reported in 1985 with the development of the first antiretroviral compound [29].  This 
compound was called Retrovir (zidovudine, AZT) and became the first drug in the family of 
nucleoside reverse transcriptase inhibitors (NRTI). AZT targets the reverse transcription process 
of HIV replication cycle.  AZT is a nucleoside analog, during reverse transcription the analog 
competes with the natural Deoxyribonucleic acid resulting in strand termination. Since AZT, 
several NRTI and other families of drugs targeting the replication cycle of HIV have been 
discovered. As of 2010, the FDA has licensed twenty-five antiretroviral drugs [30, 31]. These 
drugs can be grouped based on the mode of action and are placed into one of the following 
groups: nucleoside reverse transcriptase inhibitors (NRTI), nucleotide reverse transcriptase 
inhibitor (NtRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor 
(PI), co-receptor inhibitor (CRI), integrase inhibitor (INI), and fusion inhibitor (FI) [32]. Figure 7 
highlights licensed drugs and the mode of action of each group of drugs. 
In 1996, the first use of combination drug therapy was attempted using a protease 
inhibitor that was combined with an NRTI [33]. Combinational therapy confirmed that there was 
a longer period of undetectable or reduced viral loads as well as recovery of CD4+T cells in the 
blood. Combination therapy or HAART is now the treatment of choice for HIV infected 
individuals and results in various clinical outcomes [34, 35]. Individuals on HAART need to be 
monitored at all times to ensure the combinational therapy is effective and does not result in viral 
rebound and generation of escape mutants. Individuals on HAART will need their treatment 
regimen adjusted upon development of viral resistance [36, 37].  In addition to viral resistance, 
HAART is highly toxic to patients resulting in reduced patient compliance [38, 39].  Moreover, 
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HAART treatment is expensive and therefore people living in developing countries have less 
access to drugs, even though these are the epidemic locations. Based on surveys and clinical 
research, the WHO has identified factors that need to be considered to determine HAART 
treatment in an adult [40]: 1) suitability of drug combination, 2) licensing of drugs by national 
regulatory department and recommended dose, 3) toxicity profile of the drug, 4) availability of 
laboratory monitoring, 5) potential of maintenance and adherence to treatment, 6) prevalence of 
co-existing infections (e.g. tuberculosis), 7) child bearing age, 8) availability of local and 
international manufacturers, and 9) price and effectiveness of drug. 
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Figure 7: Diagram showing licensed antiretroviral HIV drugs. 
(JM Kilby - Expert opinion on investigational drugs, 1999 - informahealthcare.com) 
 This schematic highlights licensed drugs used in HIV treatment and the step of replication they 
target. 
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One of the complications that an individual can experience on HAART is immune 
reconstitution inflammatory syndrome (IRIS) [41]. The hallmark of IRIS is a contradictory 
worsening of an existing infection or disease process or the appearance of one soon after 
initiation of therapy [42]. It is the result of unbalance reconstitution of effector and regulatory T 
cells, leading to an uninhibited inflammatory response in patients treated with ART. IRIS is 
usually associated with fungi, herpes viruses and mycobacterial infections. IRIS occurs in 
individuals recovering from immunodeficiency. Criteria for IRIS are: 1) Response to antiviral 
therapy by: viral loads >1 log10/ml decrease in RNA level, 2) symptoms cannot be alleviated by: 
clinical course of treatment, medication side effects or toxicity, treatment failure or complete non 
adherence [43].  IRIS is also recorded in individuals with HIV co-infections such as tuberculosis 
[44]. Additionally, individuals on HAART develop other diseases such as cardiac and metabolic 
complications that are affiliated with aging [45]. The side effects of HAART treatment and 
limited availability in HIV endemic areas are the drive for development of new immunotherapies 
for HIV. 
1.4 HIV VACCINE DEVELOPMENT 
1.4.1 Viral and Immune Challenges 
Several factors have contributed to the delay of HIV vaccines and therapeutics. These factors can 
be grouped into two main categories: 1) intrinsic viral characteristics and 2) viral and host 
interactions. The intrinsic viral properties of HIV, such as rapid replication, virus mutation, virus 
recombination and viral integration, have been obstacles in drug and vaccine development [46, 
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47]. One of the major problems in HIV vaccine development is the high sequence variability of 
viral isolates [48, 49]. The classification of HIV into clades is covered in the HIV nomenclature 
proposal now found on the Los Alamos HIV Sequence database website [50]. A major 
contributor to the high variability of the virus is the lack of proof reading activity present in the 
viral polymerase (reverse transcriptase) combined with rapid replication rate. Such a 
combination allows for emergence of viral isolates that can evade the immune response elicited 
to older viral sequences. The constant escape from immune surveillance results in a constant 
need for “catch up” by the immune response. Another reason for increased variability is the 
ability of the virus to genetically recombine [51].  Due to the possibility of superinfection, (a new 
infection occurring in a patient having a preexisting infection) viruses from different clades can 
be present in the same cell during replication and may result in recombinant viruses.  For 
example, a virus classified A/E has an envelope derived from a clade A virus and Gag proteins 
derived from a clade E virus.  The other major viral property that works against effective therapy 
and viral clearance is viral integration.  HIV contains a viral integrase responsible for integration 
of the HIV provirus into the DNA of an infected cell [52]. Provirus integration is an essential 
part of replication [53]. This integrated viral DNA results in both establishment of viral 
reservoirs in the host and disruption of the immune responses against the infecting virus [54-57]. 
These viral reservoirs are a source of actively replicating viruses in individuals who have 
controlled infection and have undetectable levels of virus [58-60].  HIV reservoirs contribute to 
the lack of virus eradication and the need for continuous HAART therapy by HIV infected 
individuals to prevent virus rebound [61]. Latent reservoirs allow the virus to persist as genetic 
information in the form of a stable integrated provirus. Therefore, poor compliance and 
inadequate suppression therapy may lead to drug resistant viruses and limiting treatment options. 
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Viruses in these reservoirs are genetically similar and devoid of resistant viruses. Even though 
the latent reservoirs guarantee lifelong viral persistence, HAART therapy can suppress viral 
evolution over time as long as the toxicity induced by the regimen can be overcome.   
The lack of a defined correlate(s) of protection for HIV is a major obstacle in vaccine and 
therapeutic development.  Humoral immune responses were initially proposed as a correlate of 
protection.   Passively administering anti-HIV antibodies to experimental animals results in 
protection from infection [62-64].  The first prophylaxis vaccine to enter phase III trials, 
AIDSVAX by VaxGen, induced antibodies to HIV vaccine envelopes, but the vaccine was not 
efficacious [65].  The failure of the initial studies brought into question the role of humoral 
responses as the correlate of protection. The antigens used in these studies, monomeric gp120 
and monomeric gp160, are not the functional unit of the HIV envelope. The HIV envelope is 
trimeric on the surface of the virus particle. Studies using trimeric envelope immunogens 
improve the induced humoral responses [66-68].  Also, the recent vaccine trial in Thailand 
(RV144) provided data to support the possibility that the presence of binding antibodies to 
envelope may be the HIV correlate of protection (the RV144 clinical trial will be discussed later) 
[69]. 
Many investigators have designed preventative vaccines for HIV that induce immune 
cellular responses [70-72].  Data from preclinical studies, as well as infected individuals, show 
that an effective cellular response was able to control viral replication and resulted in reducing 
progression to AIDS [73, 74]. Coming on the heels of failed humorally-driven trials, the 
certainty of developing a preventative vaccine is questioned and preventing progression to 
disease by cellular immunity is proposed as an alternate focus. Vaccines aimed at eliciting 
cellular responses for preventing infection or disease progression have also not been successful. 
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In 2007, the Merck HIV vaccine trial used adenovirus to deliver HIV genes gag, pol and nef.  
The trial was stopped after intermediate data analysis showed no supportive evidence to continue 
[75].  It appears that pre-existing immune responses to the adenovirus may have increased 
susceptibility to infection. The immune correlate(s) for preventing infection and prevention of 
disease symptoms (i.e. control of infection) may be different [76].  In the case of preventative 
vaccines, an effective initial response to the virus is needed. At the time of the initial assault, the 
immune system is not dysfunctional.  In contrast, during HIV therapy the immune system is in a 
state of dysregulation due to the constant tug of war with the virus infection [77-79]. Figure 8 
and Table 1 below simplifies the current knowledge of immune dysfunction and pathogenesis of 
HIV infection [80]. Immune dysfunction has been identified in lymphocytes (T and B cells), NK 
cells, macrophages and increase or decrease in the levels cytokine secretion. The HIV 
immunotherapeutic field does not only have to establish the correlate for preventing disease 
progression, but has to overcome the immune dysfunction caused by the viral infection. The 
moderate success of the Thailand study and the failure of the STEP/ Merck Trial have brought 
into question both humoral and cellular immunity alone as the correlate(s) of protection. New 
vaccine designs are now aimed at inducing both humoral and cellular responses. The key to 
overcoming these obstacles faced by drug and vaccine development is continued research not 
only in terms of treatment, but also basic research of HIV and human immunology. 
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Figure 8: Pathogenesis of immune dysfunction associated with HIV 
(Fernandez, S., A. Lim, et al. (2009) Journal of HIV Therapy 14(3): 52(55).) 
The first phase occurs during acute infection and the early part of chronic infection where 
substantial depletion of memory T cells and disruption of the structure and function of the lymphoid 
tissues. This disruption of the immune lymphoid tissue set the stage for a state of persistent immune 
activation. This persistent immune activation state is characterized by increase serum immune 
makers and inflammation and depletion of memory cells (B cells, NK, and T cells).  
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Table 1: Evidence of dysfunction of the immune system of HIV infected individuals 
Fernandez, S., A. Lim, et al. (2009) Journal of HIV Therapy 14(3): 52(55). 
 
Dysfunction References 
The frequency of CD4+ T cells infected by 
HIV in vivo is too low to account for the CD4+ T cell 
loss 
[81],[82] 
Most apoptotic CD4+T cells in peripheral 
blood and lymph nodes of patients with chronic HIV 
infection are infected HIV 
[83] 
Naïve CD8+T cells, memory B and NK cells 
as well as CD4+T cells decline in HIV infection 
[84],[85], 
SIV-infected macaques exhibit a persistently 
activated immune system and rapidly progress to 
AIDS, while SIV-infected sooty mangabeys show 
normal T cell division rates and do not progress to 
AIDS. 
[86] 
HIV-2 infection is associated with lower 
levels of immune activation, which may explain the 
slower decline of CD4+Tcells compared with HIV-1 
infection 
[87] 
In mice, TLR7 stimulation unrelated to a 
virus infection induces immune activation and 
immunopathology similar to that in HIV infection 
[88] 
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1.4.2 HIV Vaccines 
To date prophylactic vaccines available for infectious diseases have been based on the 
exploitation of the humoral immune response to the infectious organism for example influenza 
A, human papillomavirus, small pox. Therefore, it was logical to focus the initial HIV vaccine 
efforts on designing vaccines that induce protective humoral responses.  The immunogen of 
choice was the envelope protein that is needed for viral entry into susceptible cells [89, 90]. 
Studies were done with the envelope proteins of both HIV and SIV in the non-human primate 
model. Some of the initial studies used either the envelope’s soluble portion gp120 or the entire 
unit gp160 to induce a humoral response [91, 92].  HIV and the SIV envelopes were used for 
vaccination in the non-human primate model to test the proof of concept. These envelope subunit 
vaccines were shown to be immunogenic in both animals and in human trials and showed no 
toxicitiy in individuals. Also, the humoral response produced by vaccination by these subunit 
vaccines was capable of neutralizing lab-adapted viruses. With such promising results in 
preclinical and early clinical trials, the lack of vaccine efficacy in human trials was unexpected 
and very disappointing. The first phase III clinical trial in pursuit of an effective HIV vaccine 
was done by VaxGen using their vaccine called AIDSVAX and consisted of a bivalent subunit 
recombinant gp120 envelope, two clade B envelopes proteins [93]. 
After showing protection against homologous and heterologous challenge in a 
chimpanzee model, the VaxGen vaccine moved into clinical trials. The controversy was due to 
the fact that the primate study was not very well powered and complete protection was not 
achieved in a suboptimal HIV animal model [92]. The initial VaxGen phase I and phase II 
studies were done with a monovalent vaccine either from the clade B HIV strains MN or IIIB, 
both lab adapted strain viruses produced in engineered bacteria. In these early trials over 1200 
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individuals were enrolled with 600 being HIV negative and the rest being infected. Results from 
the phase I and II clinical trials showed that AIDSVAX was well tolerated however 6 individuals 
were found to acquire HIV during the trial.  It was argued that the studies were not adequately 
powered to determine efficacy and in an effort to overcome this setback the vaccine that was sent 
into phase III clinical trial was bivalent with both strains MN and IIB. The vaccine trials took 
place in the US with a total of 5000 at risk women and homosexual men and in parallel in 
Thailand with intravenous drug users. The vaccines were tailored to the site such that in the US 
the vaccine consisted of envelopes from clade B and in Thailand the vaccine was made from 
envelopes from clade B and E. Trials were powered to determine efficacy and designed to be a 
three year study allowing for volunteer follow up.  The endpoints designated for the trial were 
infection measured by seroconversion and viral load measured by polymerase chain reaction.  In 
2003, VaxGen reported the failure of its vaccine trial: there was no significant decrease in 
infection in individuals who received the vaccine when all individuals were considered.  
However, the company claimed that vaccine was more immunogenic and produced higher levels 
of antibody responses in Black and Asian volunteers. Because of this finding the AIDSVAX will 
be included in a future study in combination withALVAC-HIV-vCP1521 in Thailand. This trial 
will be covered later in this section [94]. 
Since the beginning of the VaxGen trials, HIV prophylaxis vaccines have increased in 
sophistication. Given the lack of evidence to support humoral responses protecting from 
infection, another correlate of protection was needed. Numerous studies in both animals and 
humans showed that CD8+ T cells were linked to reduced viral load. These observations led 
vaccine development aimed at producing the ideal cellular responses which was not yet defined.  
In an effort to induce cellular immune responses, DNA vaccination and the viral vector-based 
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vaccines were adapted to the field of HIV.  Viral vectors used for HIV vaccine development 
include poxvirus vectors, vaccinia virus vectors, adenovirus vectors, alphaviruses vectors, 
avipoxvirus vectors, poliovirus vectors and rhabdovirus vectors [95]. The use of viral vectors 
allow for high levels of antigen production at the site of vaccination. The viral nature and the 
particle characteristic of the vector system allows for efficient uptake of vaccine by professional 
antigen presenting cells to stimulate the immune response. In addition, viral vectors have 
mucosal adjuvant effects, which are an asset in HIV vaccine development, since most infection 
transmission takes place via the mucosa. However, there is a major disadvantage to viral vectors 
especially in the case of adenovirus: the possibility of preexisting immunity may lead to adverse 
effects and reduced immune response directed towards the vaccine antigens. The first HIV 
vaccine designed to produce a cellular immune response used an adenovirus vector to deliver its 
antigens. This trial was called the STEP trial and was headed by Merck. The ability of other 
strategies to elicit cellular response has been under investigation. One of the vaccine regimens 
that had proved successful in primates to produce a cellular response is a DNA prime followed 
by protein or viral vector boost[96, 97].  
The Merck vaccine consisted of three recombinant adenoviral vectors expressing the 
genes gag, pol and nef.   Pre-clinical trials in macaques vaccinated with the modified Adenovirus 
serotype 5 expressing the genes mentioned above showed immunogenicity and reduced viral 
loads when challenged with either SHIV virus (expressing an HIV envelope) or SIVmac239 virus. 
However, the animals’ HLA played a role in the efficacy of vaccination [98].  Even with a less 
than ideal response in the primate model, as with the VaxGen vaccine, the vaccine was moved 
into clinical trials.  During clinical  pre-phase III trials should that the vaccine was safe and that 
it induced cellular immune via interferon gamma enzyme-linked immunospot assay (ELISPOT), 
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the standardized assay for cellular responses in a vaccine setting. STEP phase III trial enrolled a 
total of 3,000 healthy individuals. The endpoint for the STEP trial, as with the VaxGen study, 
was infection and viral load. Each volunteer received three injections of the three genes and 
received vaccination other two vaccinations two and three 6 months apart from each other. The 
STEP trial was stopped due to the results pointing to increased infectivity in the vaccinated 
groups.  This outcome was unexpected as the volunteers in the vaccine arm of the study had 
quality cellular responses by ELISPOT and the CD8+ T cells generated were polyfunctional [99, 
100], which was hypothesized to be needed for the ideal response to reduce viral load. However, 
the STEP results had an additional element which complicated the outcome: the rate of 
infectivity in volunteers who had a trend to higher preexisting immunity to Ad5 [75].  
The failure of the STEP trial brought into scrutiny both the use of viral vectors and the 
standards that vaccines need to accomplish in animal models before moving into clinical trials. 
In both the VaxGen and Merck preclinical trial data showed limited success in NHP but were 
allowed to move into human trials.   The urgency for an HIV vaccine, either preventative or 
therapeutic has led to vaccines without 100% protection in non-human primates moving into 
clinical trials.  In the case of the viral vectors, overcoming the hurdle of preexisting immunity 
has involved modifying vector delivery and engineering vectors to prevent a reoccurrence of the 
Merck trial.  For adenovirus vectors specifically, the following strategies have been proposed: a) 
immunosuppression of Ad responses by transiently depleted responses to the vector, b) create an 
artificial envelopes which results in a lack of recognition by the immune system, c) use 
alternative Ad serotypes which are rare in the human population, d) modify the vector to use 
alternative receptors thereby changing viral tropism and avoiding innate responses, e) use 
microspheres to encapsulate the vector and thereby by-passing the vector response and f) remove 
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early genes of the Ad and therefore there is not an initial response to the Ad vector [101]. Other 
viral vectors are also being engineered to deliver antigens and without stimulating an immune 
response to the vector itself.  One such example is the engineering of a DNA launch platform for 
alphaviruses vector.  This modification allows the alphavirus to be delivered as a DNA plasmid 
and therefore the structural proteins are not needed to enter cells to produce high amounts of 
antigens [102]. 
After the failure of the STEP vaccine trial, three different views emerged on the possible 
correlate of protection from HIV transmission: 1) humoral/neutralizing antibodies, 2) cellular or 
CD8 T cells and 3) a balance of humoral and cellular responses, the results of the next phase III 
vaccine trial were of great interest.  The ALVAC and AIDSVAX clinical trial in Thailand 
enrolled 16402 healthy men and women between the ages of 18-30 years into the study [69].  
The ALVAC vaccine contains a clade E envelope with a gag/pol from clade B and the 
AIDSVAX vaccine is the B/E vaccine covered in the previous section. The vaccine trial covered 
multiple centers and the individuals that were randomized into placebo or vaccine groups. 
Vaccine groups received four injection of the canarypox virus vector vaccine ALVAC, followed 
by two booster injections with the AIDSVAX B/E recombinant gp120. The endpoints for the 
trial were HIV infection and early viremia after the first 6 months and every 6 months thereafter 
for 3 years.  Measurement of cellular immunogenicity was done by interferon gamma ELISPOT 
and intracellular cytokine staining following stimulation with antigens gag and envelope [103].  
Humoral responses were measured for binding antibodies to various gp120 envelopes and p24 
(gag core).  T cell responses via ELISPOT showed a 19.7% induction in vaccinated individuals 6 
months after the final vaccination. In addition, greater cytokine responses were measured in the 
CD4+ T cells of vaccinated individuals. Binding antibodies to the envelopes MN and A244 
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present in the vaccine were similar and had a geometric mean titer T-1 of 31,207 and 14588 
respectively. There were only mild to moderate adverse effects mainly at the site of injection, 
confirming findings in preliminary studies. There was no significant difference in individuals 
who became infected whether or not they received the vaccine.  Nonetheless, there the study 
recorded a 31.3% protection rate using a 95% confidence interval.  Even with the moderate 
outcome, this was the first time any efficacy was reported in an HIV vaccine trial. In addition to 
being of such low efficacy, there was still no identified correlate of protection.  The only 
parameter that showed any potential as a correlate of protection was antibody binding to 
envelopes. This vaccine trial infused a new hope into the HIV vaccine field, showing that 
protection from infection was possible. 
 Some of these challenges include vaccine design to overcome variability and inducing 
the appropriate immune response at the mucosal surface. Strategies being used to overcome virus 
variability are using centralized sequences, usually based on envelopes of one or multiple clades, 
and polyvalent vaccines consisting of multiple genes of HIV from one or multiple clades [104] 
[105]. To induce mucosal immunity different vaccine strategies including vaccination at the 
mucosa (oral or vaginal in primates) and use of adjuvants are being used. However, this task is 
difficult one since the immune environment during infection and what is needed to prevent 
infection is not well understood or known. 
1.4.3 Animal Models 
Another hurdle in the field is the use of an appropriate animal model for testing immunogenicity 
and efficacy of the vaccines.  To date, macaques infected with SIV or SHIV are the most widely 
NHP as an animal model in AIDS research. Other models that have been used, include 
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chimpanzees infected with HIV-1, cats infected with feline immunodeficiency virus (FIV), 
rodents including humanized severe combined immunodeficiency mice (SCID/hu mice), and 
guinea pigs and rabbits mainly used for immunogenicity of vaccines [106, 107]. Each animal 
model has its pros and cons. In the case of chimpanzees, while these animals can be infected 
with HIV-1 the replication of the virus is not as robust as seen in humans and they do not 
progress to any immunodeficiency disease. However, vaccine efficacy may be valuable since 
there can be a direct challenge of HIV and not SIV or SIV/HIV chimera [92].  The other 
drawback to chimpanzees is the cost of the model since they are an endangered species.  Due to 
their protective status after a study is done these animals are required to have post trial care 
which requires a huge budget. Such cost limits the number of animals afforded for a study 
thereby diminishing any chance for statistical significance and usually does not justify its use.  
Two less expensive models in which the appropriate numbers of animals needed to reach 
statistical significance can be achieved are FIV in cats and rodents. FIV in cats is a good model 
because it is a naturally occurring lentivirus infection and disease.  During FIV infection, cats 
also experience CD4+ T cell depletion [108, 109].  The FIV model has been used to better 
understand transmission and immunopathogenesis.  Given these characteristics, this model 
provides a less expensive option for beginning in vivo studies of antiviral drugs and also 
emergence of resistance to antiviral drugs [110]. One of the more poorly understood aspects of 
HIV is transmission and mucosal immune responses.  Human studies are limited for analysis of 
mucosal immunity and research lies heavily on animal models, hence one of the areas of interest 
in the FIV /cat model. Although the feline model is attractive, the viruses HIV and FIV are 
significantly genetically different and the immune system of cats does not mimic that of humans 
[111].  Additionally, an FIV infection results in the infection of not only CD4+ T cells but also 
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CD8+T cells and B cells [112]. This phenomenon of infection of multiple types of lymphocyte 
cells is not seen during HIV infection.  
One of the major benefits of rodents in science is the inexpensive, reduced space needed 
for housing and the ease of repeating experiments (e.g. BaLB/c).  For this reason, many 
preliminary experiments evaluating vaccine immunogenicity are usually performed in mice. 
However, the drawback of the rodents is the inability to be infected with HIV, which has limited 
its use as a model.  To overcome the inability of HIV to infect mice, the SCID/hu mouse was 
developed. This model allows for the dissection of individual components of a human response 
to vaccines and its impact on HIV infection [113].  Nonetheless, HIV virus replication in this 
model, like the chimpanzee, is limited and the humanized mice do not mimic the pathogenesis of 
developing immunodeficiency.  Despite these limitations,  HIV dissemination can be evaluated 
in this model [114]. Over the years this SCID/hu model has evolved from just reconstituting 
immune cells to completely reconstituting all hematopoietic lineages by lymphoid organs such as 
bone marrow, liver and thymus of human origin [115]. 
NHPs most often used for HIV/SIV studies are rhesus macaques, cynomologous 
macaques and pigtail macaques. The NHP macaque SIV infection model allows for insight into 
initial infection and pathogenesis with the added advantage that SIV shares the same receptor as 
HIV: CD4.  In addition, SIV and HIV are genetically similar and SIV can be modified to allow 
investigation of certain proteins to investigate their specific role in infection and/or pathogenesis 
[116].  The macaque model can also be infected with HIV-2, but not HIV-1, to overcome the 
dilemma of chimeric viruses when SIV genes are replaced with the gene of interest from HIV are 
used. Additionally, the pathogenesis of NHP SIV infected model, is similar to the pathogenesis 
of HIV-1 in humans and not only allows for prophylactic drug testing, but also drug therapy for 
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viral infection and disease [117]. Furthermore, the macaque model has been used to investigate 
infection using multiple routes of infection: oral, intravenous, intra-vaginal, and intra-rectal 
thereby mimicking human transmission. 
Extensive use of the NHP model has resulted in the ability to mimic different outcomes 
of infection as is seen in humans.  The outcomes of infection and disease progression are 
dependent on host selection and the SIV clone chosen for infection. The different outcomes of 
disease are similar to those observed in HIV human infection: from high viremia to control of 
viremia and slower disease progression to rapid progression to disease. Multiple NHP have been 
infected by different SIV and the infection and disease progression are being studied in order to 
identify elements that can aid in development of new treatments and/or preventative vaccines 
[118-120].  The field of animal AIDS modeling has also gone on to model and compare juvenile 
and adult infection, vertical transmission from mother to offspring and expanded the species of 
NHP used to include African Greens. While the NHP model provides a chance to collect an 
immense amount of knowledge, an important caveat is that the model remains a surrogate of the 
actual infection being studied and there are limitations.  The major limitation of the NHP model 
is the fact that HIV does not infect most monkeys except for gibbon apes and chimpanzees [121]. 
However, infection of gibbon apes and chimpanzees is usually not associated with clinical 
disease and haematological abnormailities [107, 121, 122]. Other differences between humans 
and NHP that may be relevant to the disease include the difference in composition of bacterial 
flora in the gut [123], genome differences and the biology at subcutaneous vaccination sites 
[107].  Differences in bacterial flora may influence mucosal immunology patterns that may affect 
mucosal vaccine responses especially if administered orally. Mucosal response to vaccination is 
important in HIV vaccination since most infection occur via a mucosal route. A study by Gibbs 
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et al. identified that there were more active immune genes in rhesus macaques genome than in 
humans [124]. These genome differences support the need for cautious interpretation of data 
collected from rhesus macaque model. Differences in composition and distribution of muscle 
fibers, prevalence of interstitial and intra-tissue fat and tissue vascularization can directly 
influence vaccination distribution, diffusion of the formulation, its  rate of clearance and the 
types of host cell encountered. These differences may contribute to differences in immune 
responses induced by vaccination.  
1.4.4 Methods used to overcome Diversity 
1.4.4.1 Centralized Vaccine 
 
The aim of centralized vaccines in HIV vaccine development is to overcome the high diversity of 
the virus.  The three main methods for developing centralized vaccines are consensus, center of 
tree and ancestral [125-129].  These vaccines are made in an effort to reduce the differences 
between the vaccine antigen and circulating viruses while maximizing the breadth of reactivity 
coverage of the immune response.  The consensus method is more likely to have epitopes 
relevant to current epidemic strains than either ancestral or center of the tree [126].  The 
ancestral sequences are predicted based on older, non-contemporary sequences. Consensus 
vaccines based on various HIV immunogens including Gag and Env have been studied [130, 
131].  Over 95% of the global epidemic is due to HIV-1 group M viruses.  Therefore, most of the 
consensus vaccines being studied are based on clades within group M or on Group M as a whole. 
These consensus vaccines are antigenic and immunogenic and elicit stronger and more diverse 
immune responses than vaccines based on primary sequences [132, 133]. Consensus vaccine 
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studies elicit in cross-clade neutralizing antibodies [133-135].  Consensus HIV-1 Env vaccines 
have also elicited broad cellular and humoral immunity in NHPs [136]. 
1.4.4.2 Polyvalent Vaccines 
Like centralized vaccines, polyvalent vaccines are used to increase the breadth and strength of 
immune responses elicited by a given vaccine [137]. Unlike centralized vaccines polyvalent 
vaccines are made up of multiple antigens that may consist of a variation of the same antigen 
(multiple primary Envs from different strains) or multiple antigens found in the pathogen (Env, 
Gag, Pol). These vaccines have been tested in preclinical and clinical trials where they are safe 
and provide some level of protection [138]. In polyvalent vaccine studies in mice and primates, 
there has been evidence of broadly reactive humoral and cellular immune responses. A human 
clinical trial by Wang et al. showed that a polyvalent DNA prime–viral vector boost vaccination 
results in cross-subtype antibody and cellular immune responses [139].  Polyvalent vaccines 
have also elicited protection and viremia control in preclinical NHP trial studies [140].  
Polyvalent vaccines have been successful in against other diseases such as influenza and human 
papillomaviruses (HPV). 
1.5 ADJUVANTS 
The first vaccines used in humans were either live attenuated or whole killed organisms that 
induced long lasting immunity with little or no booster shots to maintain immunity. However 
these vaccines are reactogenic, induce mild disease and have the possibility of reverting to 
virulence [141]. Live attenuated and whole killed vaccines are not suitable for 
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immunocompromised individuals. Also, the possibility of reversion and contamination of live 
organisms in killed bacteria preparations make this vaccine method too risky in the case of 
diseases such as HIV. Since Jenner’s first vaccination experiment with cowpox, a better 
understanding of the immune response to pathogens and improve technology has led to safer 
subunit vaccines (protective antigen of an organism e.g. bacterial toxin). These subunit vaccines 
are less immunogenic than attenuated or killed vaccines and require multiple booster shots. Early 
studies by investigators such as Glenny and colleagues showed proof of concept that immune 
responses elicited by subunit vaccines can be improved using substances termed adjuvants [142]. 
Glenny reported a vast increase in anti-toxin antibodies in guinea pigs, when the diphtheria 
toxoid vaccine was with alum versus untreated toxoid. An immunological adjuvant can be 
defined as a substance that works to accelerate, prolong and /or enhance an antigenic–specific 
immune response when combined with a purified antigen [141, 143-145]. 
1.5.1 Adjuvants mechanism of action 
Adjuvants work in a variety of ways. The mechanisms of action can be classified into five main 
categories: i) antigen clustering, ii) size of vaccine particles, iii) antigen depot, iv) targeting 
vaccines to particular cells and v) stimulating the innate immune pathways [141].  
i) Antigen clustering: Most pathogens have surfaces consisting of repeated 
structures such as lipopolysaccharide (LPS) on gram negative bacteria. These 
high order structures are detected by the immune system enhancing antigen 
uptake and recognition and activation of B cells. Pentraxins, natural IgM, 
mannose binding lectin, C-type lectin all recognize highly repetitive antigens. 
Clustered antigens had been shown to efficiently activate B cells through their 
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surface immunoglobulin receptor resulting in increased proliferation and 
differentiation and subsequently higher titers [146]. Order clustered arrays of a 
component of the cell wall of yeast and fungi beta-glucan was shown to activate 
dectin-2 signaling when presented as a particulate coating [147, 148]. The beta-
glucan coating triggered phagocytosis and immune activation. Ordered 
particulate surfaces are also bound by IgM and complement components 
allowing more efficient uptake by lymph node macrophages which transfer the 
antigens to follicular dendritic cells. The dendritic cells maintain the antigens to 
allow long-term presentation to B cells in the lymph node leading to increase 
immunity [149].  
ii) The size of the vaccine particle affects its cellular uptake and migration patterns 
after administration. Particle sizes of ~40nm are more efficiently taken up by 
dendritic cells [150, 151] and more likely to induce interferon gamma  (vital in 
innate and adaptive viral and intracellular pathogens) [151]. While larger 
particles (>200nm) need to be transported from the injection site to the lymph 
nodes by monocytes, neutrophils and dendritic cells and induce more IL-4 from 
helper T cells (Th2: humoral immunity) [151-153]. Having this knowledge and 
vaccine delivery tools such as liposomes and polymers multiple vaccine vehicles 
can be tested. 
iii) Maintaining and antigen depot: One of the drawbacks to non-replicative vaccines 
is the need for repeated vaccinations due to the short-life of the antigen. 
Follicular dendritic cells are known to maintain antigens in the lymph nodes 
allowing for interaction with antigen specific B and or T cells. If the same 
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principle is applied to vaccines, persistent antigen presentation would allow for 
reduce number of required vaccinations for prolonged immunity. Examples of 
methods used to contain antigens are micro-particles and slow release implants 
[154]. The use of antigen depot methods results in slow release of the antigen 
overtime and protects the antigen from quick degradation allowing for persistent 
immune stimulation [155]. 
iv) Targeting to specific cells:  Antigens are fused with antibodies or triggering 
molecules that bind specific cell receptors (e.g. C3d targets B cells) [156, 157]. 
Cell types that are usually targeted are dendritic cells [158, 159] because of the 
most effective antigen presenting cells and B cells because antigen specific 
antibodies are the goal of the vaccine administered. Antibodies can neutralize 
toxins, inhibit cell invasion, or work with T cells in antibody mediated cellular 
cytotoxicity.  
v) Stimulating the innate immune pathways: The innate system does not only alert 
the adaptive system of a pathogen but also dictates the response to a particular 
infectious agent. The discovery of pathogen-associated molecular patterns 
(PAMPS), pattern recognition receptors (PRRs) and C-type lectin receptors has 
shown the importance of the innate system in modulating the response to 
immune invaders. Innate immune receptors dictate the expression and activation 
of distinct pathways in the cell leading to induction of immune modulating 
molecules such as cytokines, chemokines, leukotrienes and prostaglandins. Table 
1 has a list of currently identified innate receptors, the ligands, location and 
outcomes upon activation. New vaccine production and purification techniques 
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removed most of the ligands required to activate these innate ligands (e.g. LPS 
and viral RNA genomes). Hence the use of adjuvants formulations with vaccines 
such as toll-like-receptor (TLR) agonist allows for manipulation of these innate 
pathways to elicit an effective immune response to a specific antigen. TLR 
ligand monophosphoryl lipid A (MPL) is formulated with alum in the FDA 
approved HPV vaccine and increases the immunogenicity of the vaccine 
reducing the number of doses required for a sufficient antibody production [160].  
1.5.2 Types of adjuvants 
Adjuvants can be divided into main categories based on the era of discovery: i) classical and II) 
novel adjuvants. The classical adjuvants include aluminum salts, emulsions and liposomes and 
virosomes. The novel adjuvants include TLR agonists, Saponins, Immune stimulating complexes 
and adjuvants systems. 
1.5.2.1 Classical Adjuvants 
a) Aluminum salts (alum): Alum was the first licensed adjuvant [161, 162]. The first use 
of aluminum salts was with diphtheria toxin and it was assumed that alum worked as 
an antigen depot [142]; since then that theory has been disproven. Recent studies have 
shown that alum allow antigens to be presented in a particulate form allowing more 
efficient internalization of the antigens by antigen presenting cells (APC) [163]. 
Additionally alum has been shown to activate components of the inflammasome 
complex (member of the NOD-like family of PRRs) resulting in the release of 
proinflammatory cytokines such as IL-4, IL-5, IL-1β and IL-18 [164, 165]. Alum is 
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also associated with a Th2 or humoral responses. Alum is used in a number of 
vaccines, including vaccines for hepatitis A and B, HPV, Streptococus pneumonia, 
pediatric diphtheria, tetanus and pertussis. 
b) Emulsions: Emulsions are of two main categories either water in oil or oil-in-water 
emulsion. The first of these adjuvants was the water in oil emulsion incomplete or 
complete Freund’s adjuvant. Freund’s adjuvant was too reactogenic for use in humans 
and were discontinued [141]. Since Freud adjuvant new water-in-oil emulsion such as 
Montanide emulsion are being tested for therapeutic vaccines in clinical trial [166].  
Oil-in-water emulsions are postulated to involve innate inflammatory responses, APC 
recruitment and activation, elicitation of cytokines and antigen persistence at the site 
of vaccination [167]. The oil-in water emulsions have been successful in human trials 
and licensed vaccines. MF59 an example of an oil-in water emulsion adjuvants 
became a licensed adjuvants used in the seasonal influenza vaccine Fluad™ in 
humans [168]. Clinical trials with MF59 have resulted in enhanced humoral and 
cellular responses to pathogens such as HIV, Influenza, and HSV [169]. 
c) Liposomes and Virosomes: Liposomes are synthetic lipid layer nanospheres used to 
encapsulate antigens [170]. Virosomes are empty envelopes of the influenza virus. 
Both liposomes and virosomes act as vaccine delivery systems [171, 172], with 
virosomes having the additional advantage of having a viral envelope aiding in cell 
uptake and membrane fusion to aid in antigen delivery [173]. Virosomes have been 
used in licensed vaccines such as Inflexal™, and Epaxal ™. The Inflexal™ influenza 
vaccine is immunogenic in all age groups, even in the immunocompromise elderly 
[174, 175].  
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1.5.2.2 Novel Adjuvants 
a) Toll-like-receptor agonists (TLR): These adjuvants are an example of 
immunoenhancers. Immunoenhancers are adjuvants that work by direct stimulation of 
the innate system (Table 2) [176]. They act on pathogen-associated molecular 
patterns such as TLR on innate cells such as monocytes, macrophages, and dendritic 
cells. TLR agonists include: 1) MPL (safe formulation of LPS) interacts with TLR4, 
2) immunostimulatory sequences of microbial DNA eg. CpG oligodeoxynucelotides 
(CpG ODNs) interacts with TLR9, 3) Imidazoquinolines (eg. Imiquimod, 
Resiquimod) interacts with TLR7 and TLR8. MPL has shown to stimulate the 
expression of co-stimulatory molecules and cytokine release improving the both the 
quantity and quality of humoral and cellular immune responses depending on the 
antigen [177-179]. CpG ODNs induce inflammatory cytokines such as TNF-α, IL-1, 
IL-6, IFN-α, and IFN-γ and have shown to induce Th1 immunity (cellular responses) 
and cytotoxic T-lymphocyte responses [180]. Imidazoquinolines induce the same 
immune response as RNA binding to TLR [181]. Imiquimod formulated with a 
prototype vaccine has demonstrated extend both the duration and the extent of 
protection against HSV in mice [182]. 
b) Saponins: These substances are immunoenhancers derived from plants. Quil A 
(QS21) is derived from the back of a tree called Quillaja saponaria [183, 184]. QS21 
enhance antigen presentation to APCs and predominantly induces cytotoxic 
lymphocyte and Th1 and Th2 cytokine secretion upon animal vaccination [185, 186]. 
Saponins are now being formulated into the latest novel adjuvants called adjuvants 
systems [183]. 
 42 
c) Immune stimulating complexes (ISCOMs): ISCOMs are cage-like complexes 
composed of lipids, cholesterol, antigen, and Quil A. The hydrophobic interactions of 
the ISCOM trap the antigen and allows for more efficient endocytosis by APCs. 
These adjuvants has resulted in enhanced humoral and cellular responses in animal 
models [187]. ISCOMs have also been modified to exclude antigens form the formula 
called ISCOMATRIX, allowing the adjuvant to be used to any antigen [188].  
ISCOMATRIX presents antigens by both MHC class I and II pathways [189]. In 
addition ISCOMATRIX increases the longevity and magnitude of humoral immune 
response [189-191]. Currently these adjuvants are being investigated for Influenza, 
HCV, and cancer [192-194].  
d) Adjuvant Systems: The adjuvant systems combine the characteristics of both classical 
and novel adjuvants. These systems allow the immune response elicited by vaccine 
antigens to be enhanced in more than one adjuvant. The combination of more than 
one adjuvant allows for activation and modulation of the immune system at more than 
one level [195, 196]. Some adjuvant systems include MPL and QS21 (novel 
adjuvants) combined with aluminum salts, liposomes and or oil-in water emulsions 
(classical adjuvants) to create adjuvants systems AS04, AS02, AS01 and AS05. Table 
3 describes the components of multiple adjuvant system being investigated by GSK 
Biologicals. 
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Table 2: Characteristics of currently identified innate immune receptors and their legends  
Mike de Veer ME. Discov Med 2011;12(64):195-204 
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Table 3: GSK Biologicals Adjuvant System components and applications in the late stage of clinical 
development 
Leroux-Roels G. Vaccine 2010;28, Supplement 3(0):C25-C36 
 
 
 
 
 
1.6 SHIVSF162P4 CHALLENGE 
The discovery of a monkey lentivirus which caused and AIDS-like disease following inoculation 
in an Asian macaque has now lead to the use of nonhuman primates as the preferred model for 
study HIV vaccines.  This HIV related virus is called simian immunodeficiency virus (SIV). The 
SIV genome organization is similar to that of HIV with the vpu of HIV absent and the addition of 
Adjuvant 
system Components Current applications 
AS01 MPL, QS21, liposome-based Malaria, tuberculosis 
AS03 α-Tocopherol oil-in-water emulsion-based 
H5N1 influenza, seasonal influenza, 
H1N1v influenza (Arepanrix™, 
Pandemrix™) 
AS04 MPL absorbed on aluminium salt 
Hepatitis B (FENDrix™), HPV (Cervarix™), 
Herpes simplex virus (HSV) vaccine, 
AS15 MPL, QS21, CpG, liposome-based 
cancer immunotherapy, Non-Small Cell 
Lung Cancer (NSCLC), melanoma 
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the gene vpx.  The genomic similarities of SIV and HIV do not allow infection of nonhuman 
primates with HIV except in the case of chimpanzees. Therefore, a strategy needed to be 
developed to investigate HIV genes and proteins in the non-human primate model. To overcome 
this obstacle the idea of constructing an SIV/HIV chimera (SHIV) for infecting non-human 
primates was established.  Multiple SHIVs with HIV genes such as tat, rev, env and portions of 
nef have been constructed and tested [197]. The SHIV virus used in this project was chosen 
based on its use of CCR5 use as co-receptor for infection, CCR5 has been identified as the co-
receptor used by transmissible viruses during infection. In addition the SHIV chosen has the 
ability to infect at the mucosal surface (vaginal, and rectal). Contribution of HIV mucosal sites 
(vaginal, rectal and intestinal) to the global HIV infection is estimated to more than 47.5 million 
infections [198]. For this study, the route of virus inoculation will be rectal. Furthermore, the 
SHIVs allow for the investigation of HIV proteins example HIV Env in a non-human primate 
model.  
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2.0  MATERIALS AND METHODS 
2.1 VACCINE CONSTRUCTION AND CHARACTERIZATION 
2.1.1  Consensus envelope Design 
One hundred sequences per clade were used to design consensus sequences of clades A, B, C, 
and E. These sequences were obtained from multiple sources (LANL.B. Hahn-UAB, C. 
Williamson-South Africa, P. Gupta-India, Y. Shao-China, D. Montefiori-Duke, D. Ellenberger-
CDC, G. Nabel-NIH, R. Center-Australia and the AARRP). The design of the group M 
consensus envelope was based on two hundred Env sequences representing clades A, B, C, D, E, 
F and H.  The use of the CCR5 co-receptor was identified for 75% of the Envs. Each consensus 
Envgp160 was truncated at amino acid (aa) sequence WYIK (consensus M aa 665)   to Envgp140 
and the cleavage gp120/gp41 site was mutated by replacing the arginines (R) in the cleavage site 
with serines (S). Finally, the bacteriophage fibronectin (FT) domain was inserted at the 3’ end of 
the Env sequence to stabilize the expressed Env protein as a trimer [1] Each consensus Env gene 
sequence was synthesized (GeneArt, Regensburg, Germany), cloned into the previously 
described pTR600 [199].   
Envs were expressed from a cytomegalovirus immediate-early promoter (CMV-IE) for 
initiating transcription of eukaryotic inserts and the bovine growth hormone polyadenylation 
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signal (BGH poly A) for termination of transcription. Each plasmid was amplified in Escherichia 
coli strain-DH5 alpha, purified using anion-exchange resin columns (Qiagen, Valencia, CA), and 
stored at -20oC in dH2O. Plasmids were verified by appropriate restriction enzyme digestion and 
gel electrophoresis. Purity of DNA preparations was determined by optical density reading at a 
wavelength of 260 and 280 nm. 
2.1.2 Protein Purification 
Human embryonic kidney (HEK) 293T cells were transiently transfected with 8µg DNA plasmid 
expressing one of the consensus HIV-1 Envgp140 proteins (Consensus A,B,C,E and 
SF162,YU2,ADA,R2,PVO4,SC42) and Env gp120 histag proteins (SF162, CHN19, EIIF22070, 
Q23, Q259). Following DNA transfection using Lipofectamine2000 (Invitrogen Life 
Technologies, Carlsbad, CA, USA), cells were incubated for 72 h in opti-MEM I reduced serum 
formula media (Gibco, Grand Island, NY, USA).  Media was collected and secreted Envgp140 
proteins were purified using lectin columns made from agarose galanthus nivalis (snowdrop) 
lectin (Vector laboratories, Burlingame, CA, USA). Envgp120 were purified at 4 ◦C using a 5 ml 
HiTrap chelating nickel column (Amersham Biosciences, Piscataway, NJ, USA). Briefly, the 
column was loaded with 0.1M NiSO4 (5 ml) (Fisher Scientific, Fair Lawn, NJ, USA) and 
subsequently washed with distilled water (15 ml). The HiTrap column was equilibrated with 30 
ml of Binding Buffer (20mM phosphate, 0.5M NaCl and 10mM imidazole) (Sigma, St. Louis, 
MO, USA)]. Supernatants containing His-tagged proteins were loaded into the equilibrated 
HiTrap column at a rate of 2ml/min. The column was then washed with Binding Buffer (30 ml). 
Subsequently, the proteins were eluted using 15 ml of Elution Buffer (20mM phosphate, 0.5M 
NaCl and 500mM imidazole). Eluted proteins were dialyzed in PBS using Slide–A-Lyzer 
 48 
dialysis cassettes (Thermo Scientific, Waltham, Massachusetts, USA). Proteins were then 
concentrated using Amicon ultra centrifugal filter concentrators (Millipore, Billerica, 
Massachusetts, USA). Micro BCA Protein Assay kit (Thermo Scientific, Waltham, 
Massachusetts, USA) was used to quantify proteins. Other purified envelopes used for ELISAs 
(PVO4, SC42, 6535, THRO4, AC10, RHPA, CAP210, ZM214, DU172) were purchased from 
eEnzyme (Gaitherburgs, MD, USA). 
 
1ug of each purified consensus gp140 trimer protein was loaded unto NativePAGE native 
gel (Invitrogen Life Technologies, Carlsbad, CA, USA) and separated by electrophoresis in the 
manufacture’s recommended buffers (NativePAGE running and anode buffers). After separation 
gel was silver stain using the ProteoSilver Sliver Stain kit (Sigma, St.Louis, MO, USA) 
following manufacture’s protocol.  Briefly, after electrophoresis the gel was placed in a clean 
tray with 100 ml of Fixing Solution (50% ethanol, 10% acetic acid in ultrapure water) for 1 h. 
The Fixing Solution was removed and the gel was washed with 100 ml of Ethanol Solution (30% 
ethanol in ultrapure water) for 10 min. The Ethanol Solution was decanted and the gel was 
washed twice (10 min) with 200 ml of ultrapure water. The gel was then incubated for 10 min 
with 100 ml of Sensitization Solution (1% ProteoSilver Sensitizer in ultrapure water). Following 
removal of the sensitizing solution, the gel was washed twice (10 min) with 200 ml of ultrapure 
water. The water was decanted and 100 ml of Silver Equilibration Solution (1% ProteoSilver 
Silver solution in ultrapure water) was added to the gel for 10 min. After the Silver Equilibration 
Solution was removed, the gel was washed for 1min with 200 ml of ultrapure water. The water 
was decanted and 100 ml of Developer Solution (5% of Proteo Silver Developer 1, 0.1% of 
ProteoSilver Developer 2 in ultrapure water) were added to the gel. The gel was carefully rocked 
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back and forth for 3–7 minutes until the desired staining intensity was observed. 5ml of the 
ProteoSilver Stop Solution was then added to stop the reaction. 
. 
2.1.3 Virus- Like Particle (VLP) Production 
Supernatants from COS cells (monkey kidney cells) transiently transfected with plasmids 
expressing either SIV Gag or consensus VLP were pelleted by ultracentrifugation (100,000xg 
through 20% glycerol, weight per volume) for  4 h at 4°C. Pellets were resuspended in PBS and 
stored at -20°C until needed. Protein concentration was determined using Micro BCA TM 
Protein Assay Reagent Kit (Pierce Biotechnology, Rockford ,IL. USA). 
 
2.1.4 CD4 Binding Assay 
Protein G Dynabeads (Invitrogen) were mixed to ensure homogenous suspension.  20ul of beads 
suspension was used per reaction.  Magnetic beads were washed 3x using 500ul of citrate-
phosphate buffer pH 5. Then 4µg of mouse anti-his antibody (Invitrogen Life Technologies, 
Carlsbad, CA, USA) was diluted in 35ul of citrate-phosphate buffer and was added to beads. The 
suspension was mixed at RT for 40 min. The tubes were then placed on the magnets to remove 
all unbound antibody and washed with citrate buffer 3X. Then soluble human CD4 HIStag 
(eEnzyme, Gaithersburg, MD, USA)/consensus envelope mixtures were then placed in with the 
beads and allowed to incubate for 1 hr at 4°C. Prior to this step the human soluble CD4 protein 
and consensus envelopes were at 37°C for 1 hr before being added to the beads.  After 1 hr the 
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suspension was placed on a magnet and the liquid or supernatant fraction was collected. Beads or 
pellet fractions were then washed 3X with phosphate buffer saline (PBS) and then re-suspended 
in 50ul of PBS. Then samples were separated on a 10% SDS PAGE gel, transferred unto a 
nitrocellulose membrane and probed for sCD4 or envelope using mouse anti-human CD4 at 
1:5,000 (Southern Biotech, Birmingham, AL, USA) and rabbit anti-IIIB gp120 envelope at 
1:5,000 (Advanced Biotechnologies Inc, Columbia, MD, USA) respectively. Secondary 
antibodies goat anti-rabbit IgG-HRP and goat anti-mouse IgG-HRP were used at 1:10,000 
(Southern Biotech, Birmingham, AL, USA). Western blots were developed using Pierce ECL 
western blotting substrate (Thermo Scientific, Waltham, Massachusetts, USA).  
2.1.5 Biacore 
Kienetic analyses of MAb b12 binding to HIV rgp140(s) was performed on a Biacore 3000 
(GE/Biacore AB, Inc., Uppsala, Sweden). Protein A (Pierce, Rockford, IL) was covalently bound 
to individual flow cell surfaces of a CM5 sensor chip utilizing amine-coupling chemistry. MAb 
were captured and oriented onto protein A surfaces to ensure that the MAb-envelope binding 
occurred as a homogenous 1:1 Langmuir interaction. Three-fold serial dilutions of HIV 
rgp140(s) trimers were injected over each flow cell at concentrations ranging from 0.815nM to 
66nM. The reference surface contained protein A that served to account for changes in the buffer 
refractive index and to test for potential nonspecific interactions between rgp140 and protein A.  
All runs were double referenced with a buffer alone injection serving as a negative control. Upon 
completion of each association and dissociation cycle, surfaces were pulsed with regeneration 
solution. Rhesus MAb association rates (ka), dissociation rates (kd), and affinity constants (KD) 
were calculated with BIA evaluation 4.1.1 software (GE/Biacore AB, Uppsala, Sweden). The 
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goodness of each fit was based on the agreement between experimental data and the calculated 
fits, where the 2 values were below 1.0. Protein A-MAb surface densities were optimized to 
minimize mass transfer, and kinetic analyses demonstrated that the binding interactions were not 
significantly mass transfer limited. 
2.2 ANIMAL VACCINATION AND IMMUNE RESPONSE ANALYSIS 
2.2.1 Animal Vaccination 
Balb/c mice (Mus Musculus (6-8 weeks old) were used for the initial animal characterization 
experiments. These animals were purchased from Harlan Sprague Dawley (Indianapolis, IN, 
USA) and housed in microisolator units with access to free food and water. All vaccinations 
were given in the quadriceps and formulated with Imject® alum adjuvant (Imject® Alum, Pierce 
Biotechnology; Rockford, IL, USA) in a 50µl total volume. Mice were vaccinated with 10ug or 
20ug VLP of protein at weeks 0, 3 in the initial study and weeks 0, 4 the second mice 
experiments.  In both studies mice were vaccinated in the quadriceps.  Each mouse group 
consisted of ten (10) animals. 
 
Rhesus macaques (Macaca mulatta) were used for all non-human primate experiments. 
All animals were cared for adhering to USDA guidelines for laboratory animals. Rhesus 
macaques were anesthetized using 10-20mg/kg ketamine and vaccinated intramuscularly in the 
quadriceps and formulated with Imject® alum adjuvant (Imject® Alum, Pierce Biotechnology; 
Rockford, IL, USA) in a 1ml total volume. Vaccinations were completed at weeks 0, 4 and 8.  
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Twelve animals were divided into three (3) groups, four animals per group. Group 1 or Mock 
animals received adjuvant only. Group 2 or Polyvalent Consensus animals received a total of 
300ug of total purified protein per vaccination (equal amounts of Consensus A, B, C, E 
envelopes). Group 3 or Consensus M animals received a total of 300ug total protein per 
vaccination (Table 4).  
2.2.2 Sample Collection and Processing 
For blood sample collection animals were anesthetized with a mixture of ketamine/xylazine. 
Anesthetized mice were bled at weeks 4 and 6 via the retro-orbital plexus, and blood was 
transferred to a microcentrifuge tube. Tubes were centrifuged and sera were collected and frozen 
down at -20°C. During sample collection rhesus macaques were anesthetized as mentioned 
above and bleed via the femoral vein at various time points. Monkey Peripheral blood 
mononuclear cells (PBMC) were isolated from anti-coagulated EDTA collected blood by density 
gradient centrifugation over histopaque (Sigma, St.Louis, MO, USA). White buffer layer was 
collected and treated with ammonium-chloride-potassium (ACK) lysis buffer to remove any red 
blood cells. Cells were then washed, counted, frozen and stored in liquid nitrogen until needed. 
Whole blood collected in red cap tubes were spun down at 2,000 rpm for 25 minutes for serum 
collection.  Sera was then pulled off and stored at -80°C until needed. 
2.2.3 Enzyme- Linked Immunosorbent Assay (ELISA) 
Costar 96 well plates were coated (Costar flat bottom high binding) with 100ul of Concavalin A 
(50ug/ul diluted in PBS) per well for 1 hr at room temperature. Plates were then washed 2X with 
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PBS and coated overnight at 4°C with 50ng/ well of desired coating antigen (purified protein). 
Plates were then washed 4X with PBS and blocked with 200ul of 5% non-fat dry milk-PBS for 2 
hr  at RT. Plates were then washed 4X with PBS, and sera was added. For endpoint titers sera 
was serially diluted 1:2 across the plate with a starting dilution of 1:100. For cross binding 
ELISA, sera were pipette into the wells of a coated plate at 1:100. Sera were left on the coated 
plates for 1 hr at RT. Serum samples were then removed and plates were washed 4X with PBS. 
Then secondary antibodies (1:5000 dilution) were used to detect both mouse and non-human 
primate sera for 1 hour at RT (goat-anti-mouse IgG HRP/ goat-anti-Rhesus IgG HRP from 
Southern Biotech). Plates were then washed and developed using 3,3’,5,5’-Tetramethyl-
benzidine (Sigma) substrate to develop for half an hour. Reaction was then stopped using 50ul 
1N Sulfuric Acid. The colorimetric change was measured at optical density of 450nm using a 
spectrophotometer (BioTek Instruments, Winooski, VT, USA). End point titer for assay was 
determined as the reciprocal of the dilution at which the well’s OD reading was above the mean 
plus two standard deviations of naïve sera.  
2.2.4 In Vitro Neutralization Assay 
Antisera were tested for the ability to neutralize virus infection in vitro using TZM-Bl cells 
indicator cells [200].  These cells express HIV receptors human CD4 (hCD4), human CCR5 
(hCCR5), human CXCR4 (hCXCR4), and a luciferase reporter driven by the HIV-1 LTR. TZM-
Bl cells were cultured in a 96 well plate in cDMEM with 10% fetal calf serum (10%) for 24 
hours prior to infection with virus.  Heat inactivated sera (56°C for 60 mins) was serially diluted 
(2 fold) and added to a standard quantity of virus (50TCID50). The sera/virus mixture was 
incubated at 37°C for 2 hr then added to the TZM-bl cells and incubated at 37°C for 48 h. Cell 
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lysates were harvested in lysis buffer (25mM Tris phosphate, pH=7.8, 2mM DTT, 2mM 1-2-
diaminocyclohexane-N, N, N’, N’-tetraacetic acid, 10% glycerol, 1% Triton X-100). Luciferase 
reagent was added was and the relative light units (RLU) were determined using a Femtomaster 
FB12 Luminometer (Zylux, Maryville, TN).  The sera dilution necessary to neutralize virus was 
calculated by the following formula (RLU of virus only-RLU of cell only)/2+ RLU cell only. 
2.2.5 Antibody Secreting Cell ELISPOT 
Mice were sacrificed two weeks post final vaccination (week 6) and spleens were harvested and 
prepared into a single cell suspension. Briefly, PVDF membrane plates (Millipore, Billerica, 
MA,USA) were coated with purified consensus envelopes at (250ng/well) and kept at 4° C 
overnight. Plates were then washed with sterile PBS and blocked with cRPMI and placed at 
37°C for ~3 hours.  Media was then removed and the single cell suspension prepared was added 
to the plates at 105 cells per well. Plates were then incubated at 37°C for 48 hours. After 
incubation, plates were then washed with PBS and incubated for 2 hrs at room temperature with 
horse radish conjugated anti-mouse IgG (Southern Biotech, Birmingham, AL USA). Plates were 
then washed as before and spots were developed at room temperature for 1 hour in the dark using 
detection substrate (NovaRED TM,Vector Labs, Burlingame, CA, USA.). The plates were then 
washed extensively with DI water and allowed to dry overnight. Spots were counted using 
ImmunoSpot ELISPOT reader (Cellular Technology Ltd., Cleveland, OH, USA.) 
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2.2.6 Viral Load Determination  
Real time PCR-based SIV viral detection assay was used to determine the viral titers post-
challenge as described in [201].  Briefly, 1 ml plasma was collected and concentrated via 
centrifugation (100,000g for 30 mins at 4°C) to pellet virus particles. Then 800µl of supernatant 
was removed and 200µl of pelleted virus solution was then added to NucliSen lysis tubes 
(bioMerieux, Hazelwood, Missouri, USA). Before RNA extraction, 10µl of 13X105 particles of 
CM240 virus (as an external normalize) were added to the NucliSen tubes. RNA extraction was 
then performed as directed by manufacturer (bioMerieux, Hazelwood, Missour, USA). A 
standard curve was generatedfor each viral load assay using SIVmac251; RNA from the 
SIVmac251 dilution series was extracted along with the external normalizer. The primers and 
probes to 67-bp region of SIV gag DNA was used for amplification were forward primer 
SIVp15f1, reverse primer SIVp15r1, and probe SIVp15P 5′-joe 
AGCCTTTATAATACTGTCTGCGTCATCTGG-quencher 3′. For the external normalize 
CM240 forward primer envE2f (6928–6949) 5’-GGACAGGGCCATGTAAAAATGT-3’, 
reverse primer 5’ENVe2r (7027–7002) 5’-TCTTCTGCTAGACTGCCATTTAACAG-3’ and 
probe envEP (6965–6977) 5’-fam CACACATGGAATTAAGCCAGTGRTATCMACTCA-
quencher 3’. 10µl of RNA was used in a 2-step TaqMan Gold RT-PCR reaction (Applied 
Bioscience, Carlsbad, California, USA). cDNA (10µl) generated by the RT-RCR reaction was 
then used for PCR using the ABI 7000 Gene detection system  (Applied Bioscience, Carlsbad, 
California, USA).. 
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2.2.7 Anti- CD8 depletion by antibody administration 
All animals in the Consensus M group were depleted of CD8+ T cells. The antibody M-T807R1 
(NIH NHP Reagent Source, Beth Israel Deacones Medical Center, Boston, MA, USA) was 
administered subcutaneously (50mg/Kg) on day 0 (Day 70 post infection).  CD8+T cell depletion 
was verified using TruCOUNT tubes (BD Bioscience, San Jose, CA, USA). 
 
2.2.8 Absolute cell count using TruCOUNT tubes 
Absolute T cell counts were done using 50 µl EDTA –collected whole blood placed into 
TruCOUNT tubes (BD Bioscience, San Jose, CA, USA). Cells were stained with a mixture of 
monoclonal antibodies CD3-PE (BD Bioscience), CD4-Amcyan (NIH NHP Reagent Source, 
Beth Israel Deacones Medical Center, Boston, MA, USA), CD8-APC-Alexa 750(eBio), CD45-
PerCP (BD Bioscience, San Jose, CA, USA). Cells were incubated with monoclonal antibodies 
for 15 mins at RT followed by the addition of 450µl BD FACS lysing solution for 15 mins. 
Samples were then placed at 4°C and analyzed within 4 hr.  Samples were collected in a BD LSR 
II flow cytometer and the data were analyzed by FlowJo software (Tree Start Inc. Ashland, OR, 
USA). T cell calculations were based on manufacture’s equation [# events in cell population/# 
events in absolute count bead region x #beads/test (provided on package) /test volume]. 
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2.2.9 ELISPOT 
The number of anti-envelope (SF162p3 and consensus M) specific interferon gamma IFN-γ 
secreting cells were determined using the non-human primate enzyme-linked immunospot 
(ELISPOT) assay (R&D Systems, Minneapolis, MN, USA).  Briefly, pre-coated anti-IFN-γ 
plates were incubated (30 min at 37°C) with (200µl) of sterile cRPMI. Plates were then seeded 
with peripheral mononuclear cells (PBMC 1x105 cells) isolated at 14 post last vaccination or 
days 7 or 14 post infection. Cells were then stimulated for 48 hours with 30ug of Gag peptide 
pools representing SIVmac239 or Env pools representing either Consensus M or SF162p3 
(overlapping peptides, 15-mers with11 amino acid overlap NIH AIDS Research and Reference 
Reagent program).  As negative and positive controls cells were stimulated with Ova peptide and 
PMA/ionomycin (50ng/500ng) respectively. Plates were then washed 4X with R&D wash buffer 
and incubated at 4°C overnight with biotinylated anti-IFN-γ. Plates were washed 4X and 
incubated with streptavidin conjugated to alkaline phosphatase at 25°C for 2 hr. This step was 
followed by 4x washes with wash buffer and a1 hr incubation at 25°C with stable BCIP/NBT 
chromagen. The chromagen solution was discarded and plates were rinsed plate with deionized 
water and left to dry before being read. Plates were read using ImmunoSpot ELISPOT reader 
(Cellular Technology Ltd., Cleveland, OH, USA. 
2.2.10 Phylogenetic Tree 
To create the phylogenetic tree the sequences of all envelopes used were submitted to the 
website phylogeny.lirmm.fr/phylo_cgi/index.cgi (managed by GForge project, funded by Reseau 
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National des Genopoles) as a fasta file. The sequences of the primary isolates were accessed 
from the genbank using their accession numbers. Using these sequences a tree was generated. 
 
 
2.2.11 Statistical Analysis 
Statistical tests were performed using Graph Prism software. Statistical significance of antibody 
test was determined by two-way analysis of variance (ANOVA) followed by the Bonferroni’s 
post-test. Post-test was used to analyze differences between the vaccine groups. Significance was 
determined to be a p<0.05. 
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3.0  SPECIFIC AIMS 
3.1 OVERALL OBJECTIVE AND RATIONALE 
A major challenge in the development of an HIV/AIDS vaccine is the ability to overcome the 
virus’ incredible envelope diversity. In these studies, two strategies were evaluated to overcome 
viral sequence diversity in Env. Polyvalent and consensus vaccine strategies increase the breadth 
of vaccine responses. Polyvalent vaccines consist of multiple immunogens to increase the 
epitopes available to stimulate a broadly–reactive immune response. The consensus vaccine is 
designed to capture the most common epitopes in an effort to decrease sequence variability 
between the vaccine and the wild type isolate. Therefore, immune responses elicited by a 
consensus immunogen are proposed to recognize multiple isolates resulting in a broadly-reactive 
adaptive response. Two separate group M vaccines are used in this study. The consensus M Env 
used in this study covers all the clades from HIV-1 group M, and the polyvalent vaccine covers 
clades A, B, C and E. The use of these consensus Env sequences was designed to address the 
problem of diversity within HIV strains by eliciting cross-protective immune responses. This is 
the first study to compare a single consensus envelope to a mixture of consensus envelopes. 
Comparing a consensus group M Env to a polyvalent clade consensus Env vaccine will address 
the question of whether a group M vaccine is sufficient to protect against a heterologous 
challenge. The characterization of the immune responses elicited by the vaccine and the 
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evaluation of the protection given by these immune responses will allow for insight into possible 
correlates of protection for HIV. Determining if a single consensus group M Env vaccine is 
sufficient for protection and eliciting an immune response that correlates with protection to viral 
challenge will impact the development of prophylaxis and therapeutic treatment in the HIV field. 
Having a single component vaccine will reduce cost of production and distribution of the 
vaccine. Therefore, the vaccine will be more affordable and accessible especially in developing 
regions such as Africa where the need for an effective vaccine is needed. 
3.2 OVERALL HYPOTHESIS AND AIMS 
Overall Hypothesis: A multi-clade vaccine expressing HIV-1 envelope proteins (con M or 
mixture of consensus envelope proteins) in their native structure will elicit a broad cross-reactive 
immune response capable of protecting from heterologous virus challenge. 
 
Specific Aim I: To construct and characterize the Consensus Envelopes gp140 trimers 
Hypothesis: All consensus gp140 envelopes will produce trimers and bind human soluble CD4 
 
Specific Aim II: To determine the vaccine regimen of Consensus Envelopes that will elicit the 
highest Envelope titer to homologous vaccine 
Hypothesis: The heterologous DNA prime containing envelope followed by purified gp140 
envelope trimer will result in the highest homologous titer compared to DNA only or protein 
only vaccinations. 
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Specific Aim III: To evaluate the immunogenicity and efficacy of the Consensus M and Poly 
Consensus Vaccines in Non-Human Primates. 
Hypothesis: Both vaccines will be immunogenic in NHP; however the Poly Consensus Vaccines 
have a better antibody breadth and be more efficacious. 
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4.0   SPECIFIC AIM I:  TO CONSTRUCT AND CHARACTERIZE THE 
CONSENSUS ENVELOPES GP140 TRIMERS   
4.1 FOREWORD 
A central question regarding development of a synthetic immunogen is whether its construction 
and design affects function or antigenicity of the native protein.  This concern is especially 
critical in the case of consensus sequences, since they do not exist in nature. The quantity and 
quality of the antibody elicited by a vaccine depends on the antigen and how it is delivered to the 
immune system. Before antigen delivery can be investigated, antigen design needs to be 
addressed. The goal of this aim was to construct these envelopes and ensure they had similar 
functional and antigenic epitopes as wild type envelopes. 
4.2 ABSTRACT 
HIV envelope consists of two non-covalently linked subunits: gp120 (external subunit) and gp41 
(transmembrane unit). The functional subunit of the HIV envelope is a trimer. Due to its critical 
role in viral entry, a tremendous amount of work is being done to develop a soluble envelope 
trimer as a vaccine candidate capable of eliciting anti-Env antibodies. In an effort to develop a 
preventative HIV envelope vaccine capable of overcoming the virus’ high diversity, consensus 
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envelopes were designed. These consensus envelopes are based on the HIV clades A, B, C, E 
and group M.  Viruses from group M, which encompasses clades A, B, C, E, have been shown to 
be responsible for most global infections. The sequences of the consensus envelopes have been 
truncated and modified to produce soluble envelope trimers. Consensus envelopes expressed as 
soluble trimers, retain their ability to bind HIV Env receptor CD4 and retained a well 
characterized cross-reactive epitope that is recognized by monoclonal antibody b12. 
4.3 INTRODUCTION 
In an infected individual, various isolates of HIV-1 exist as a mixture of closely related, but 
genetically distinct variants or quasispecies [202]. A combination of high rates of mutation, due 
to a highly error-prone replication, plus a viral production of millions of virus particles in a day 
illustrates the enormity of variants within each individual [203, 204]. In an effort to deal with the 
issues of viral diversity, strategies are being employed to construct centralized immunogen 
sequences that minimize the genetic distance to circulating viruses [205, 206]. Immunogens that 
are genetically closer to circulating variants are expected to elicit cross-reactive immune 
responses and lead to protection. Centralized sequences are influenced by sampling, 
computational inference, and recombination [207]. 
Sampling bias is a fundamental aspect that needs to be considered in the construction of 
centralized sequences. Ideally, the sample sequences should be representative of the 
phylogenetic distribution of the circulating strains and of their relative frequencies. Consensus 
(CON) and center-of-tree (COT) centralized sequences are heavily dependent on the sampling 
process, unlike the ancestral sequence (ANC) [208]. If a sample contains more sequences from 
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one clade, the resulting CON sequence would be more representative of that clade.  To overcome 
sampling bias based on sequence availability, a layered consensus strategy was performed to 
design an H5 influenza HA CON (COBRA) vaccine by our group in the field of influenza [209]. 
The size and composition of the ideal target population will depend upon this co-diversification. 
The representative population used for generating the centralized gene could be based on a 
diverse set of parameters e.g. regional location of viral isolation, year of isolation, HIV clade or 
specific co-receptor usage.  In general, the average distance between the sample sequences and 
the CON/COT sequence would likely be lower than the ANC sequence.  A few studies have 
focused on the implications of different computational strategies that define the sequences of 
centralized genes. Kesturu et al. characterized the ability of three centralized representative 
sequences (CON, COT and ANC) to minimize the genetic distances for HIV-1 env sampled from 
13 consecutive time points over an 8 year period in an infected individual [210].  During the first 
5 years of infection, all three centralized sequences effectively minimized the genetic distance to 
the existing sequences. However when the centralized sequences were compared to later virus 
variants the ANC sequence was not as effective in minimizing genetic distance.  While 
centralized sequences reduce genetic distance to circulating strains they may have an effect on 
the  predicted 3-D structural properties, the number of antigenic epitopes,  the affinity of MHC 
binding sites and number of  N-glycosylation sites [211]. Recombination is an integral part of the 
HIV-1 life cycle with an estimated number of three recombination events occurring per genome 
replication [212].  Discovery that most infected cells harbor two or more different proviruses 
[213]  give credence for recombination playing a central role in generation of HIV diversity 
[214, 215]. Due to the need for phylogenetic trees to determine COT and ANC recombination 
may mislead phylogenetic estimation  of these two sequences [216, 217]  . In contrast the CON 
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sequence has the advantage of not being biased by recombination since it is not dependent on 
phylogenetic trees. 
The purpose of centralized genes in the use of more effective vaccines is based on the 
assumption that immunogenic epitopes of the virus will be constant to some extent. In addition, 
the evolutionary arms race between the virus population and the host immune system does not 
preclude the conservation of some key epitopes.  In this study, both structural and genetic 
approaches were used to develop an envelope vaccine. Envelopes based on viruses responsible 
for most of the HIV global burden were designed using the consensus strategy of aligning full 
length amino acid sequences and selecting the most common amino acid in each position. Non-B 
HIV clades account for 88% of infections in high prevalence areas with clades C being dominant 
but including recombinants AE, AG [218], hence clades A,B,C and E and group M being chosen 
for Env consensus design.  Individual consensus envelopes of clades A, B, C, E and a consensus 
envelope of group M, which includes the clades A, B, C, E, were engineered. For each consensus 
sequence, at least 100 envelope sequences representing viruses within that clade or group were 
aligned and the most common amino acid at each position was chosen. The envelope sequences 
were then truncated and modified via mutation of the cleavage site and addition of a 
bacteriophage trimerization domain to form envelope gp140 trimers upon expression in 
mammalian cells. Studies from our lab and others have produced wild type envelope trimers in 
the same manner [1, 2]. Upon purification, the consensus envelopes exhibited characteristics of 
wild type envelopes by producing stable trimers, bound to CD4 and contained a known cross-
reactive epitope recognized by monoclonal antibody b12.  
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4.4 RESULTS 
4.4.1 Design and Construction of Consensus Envelopes 
The goal of this aim was to construct and characterize consensus envelope trimers. To 
accomplish this goal, the consensus envelope sequences were generated by selecting the most 
common amino acid at each position of a full-length envelope alignment. The consensus M 
envelope design using two hundred isolates sequences representing clades A, B, C, D, E, F and 
H.  For the individual clade A, B, C and E consensus envelopes at least one hundred full length 
envelope sequences were used for each clade. The consensus envelope gene sequences were then 
truncated at the lysine (K) amino acid (Consensus M amino acid 665) to generate a gp140 
protein that results in the expression of soluble envelope trimers.  The Env cleavage site between 
gp120/gp41 was mutated by replacing the two arginines (R) at amnio acid sequence 
VVQSEKSA with serines (S) (Consensus M amino acids 490 and 493). To stabilize the 
truncated envelope trimers, the bacteriophage fibronectin domain (FT) was added to the end of 
the Env gp140 sequence (Figure 9), as previously described [1, 2].   
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Figure 9.  Diagram illustrating envelope modifications. 
These modifications were based on previous studies by Bower et al ..[1] and Yang e. al[2] 
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4.4.2 Characterization of Consensus Envelopes 
Supernatants from 293T cells were harvested following transfection with DNA plasmids 
expressing each of the consensus Envgp140 proteins.  Individual consensus envelopes were then 
purified over lectin columns. Purified envelope trimers were separated by Invitrogen’s 
NativePAGE Bis-Tris native gels (Figure 10).  All consensus envelopes were detected by silver 
stain on native gel at ~480KD size indicating oligomerization as trimer proteins.  Env dimers 
were observed primarily for consensus C, E and M Envgp140 proteins. To investigate the antigenic 
structure, the broadly reactive monoclonal antibody b12 was used to determine binding kinetics 
to each consensus envelope by BIACORE (Figure 11). The rate of association between the 
consensus envelope trimers to b12 was similar to the rate of association between b12 to primary 
envelope trimers of YU2, ADA and R2.  The rate of dissociation of b12 from all the envelope 
trimers was similar, except for consensus B, which had a slower rate of dissociation.  Each 
Envgp140 bound to the primary HIV receptor, human CD4 (hCD4) (Figure 12). Following 
immunopreciptation of soluble human CD4 both the pellet fraction (Envgp140-hCD4 complex) 
and supernatant fraction (unbound proteins left in solution); were separated via SDS-PAGE. 
Western blots using antibodies to CD4 and the HIV envelope were used and both CD4 and 
consensus envelopes were detected in the pellet fraction. The supernatant and pellet fractions 
were stained by commassie blue for total protein.  BSA was only observed in supernatant 
fraction and not pellet fraction (data not shown).  
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Figure 10 Native gel of lectin purified envelope timers 
1µg of each purified consensus envelope was loaded onto a native protein gel and separated into their 
oligomer species by electrophoresis. All consensus envelopes were detected by sliver stain at ~480 
kDa size. The top of the gel is labeled with the consensus envelope present in the lane and the protein 
ladder values are present on the y-axis.  
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Figure 11.Graph showing interaction of envelope trimers with b12 monoclonal antibody. 
 Using surface plasmon resonance, the interaction of the consensus envelopes and b12 was 
investigated in solution.  The x-axis gives the rates of association between b12 and the envelope 
and the y-axis gives the dissociation between the envelopes and b12. The consensus trimers are 
indicated by the darker symbols on the graph and the primary envelope trimers are indicated 
by the lighter symbols. 
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Figure 12 Western blot of supernatant and pellet fractions of CD4 binding Assay 
The consensus envelopes and negative control BSA was pre-incubated with Histag soluble human CD4 at 
37°C then mixed in with magnetic beads that were pre-incubated with the anti-his antibody. Using 
immunoprecipitation (IP), sCD4 and anything bound to it was pulled down in the pellet fraction. 
Supernatants and pellet fraction was analyzed by SDS-PAGE and western blot using anti-his and anti-
envelope antibodies. Left panel: supernatants fraction.  Right panel:  pellet fraction (sCD4 and proteins 
bound). The protein ladder values on y-axis. The upper blots were probed with rabbit polyclonal anti-
envelope antibody and the bottom blots were probed with mouse anti-human CD4 antibody (Clone RFT-4g 
mouse IgG, SouthernBiotech). Lane 1:  BSA, Lane 2: Consensus M Envgp140, Lane 3:  Consensus E Envgp140, 
Lane 4:  Consensus C Envgp140,   Lane 5:  Consensus B Envgp140,   Lane 6:  Consensus A Envgp140. 
 
 72 
4.5 DISCUSSION 
Consensus vaccines are a potential strategy to elicit broadly reactive immune responses. 
Consensus envelopes have been described previously and reported to be functional as measured 
by retention of cross-reactive antigenic epitopes [128, 130, 219]. However, the synthetic nature 
of consensus envelopes requires confirmation of functional and antigenic characteristics for each 
individual immunogen. Consensus sequences can influence 3-D structure of proteins but also the 
presence of antigenic epitopes, and number of N-linked glycosylation sites.  In this aim we 
characterized the basic structural and antigenic properties of five synthetic HIV-1 gene products. 
Three questions were addressed: (i) do the modified consensus gene sequences generate trimeric 
Envelope proteins (ii) are these Envelope trimers functional and (iii) did consensus envelope 
retain antigenic epitopes?  
Each of the consensus Env A, B, C, and E amino acid sequences were compared to 
consensus M. The consensus envelopes constant regions of gp120 had ~82-~93 % amino acid 
identity to the Con M. When the amino acid sequence identity for the consensus Env variable 
regions of gp120 were compared to Con M 80-89% with the distribution of the non-homologous 
amino acid spread across V1-V5. When the consensus M was compared to the publish group M 
Env ConS by Gao et. al.  [219] the amino acid identity with the gp120 constant regions was 
~98% and variable regions was ~93%. The amino acid sequence difference did not significantly 
affect the number N-linked glycosylation sites of consensus Env A, B, C, E compared to Con M; 
the number of glycosylation sites identified to be between 30-31 sites.  
The data generated indicate that the five consensus envelopes express the same antigenic 
epitopes as Env from HIV-1 virus isolates. The envelopes contained linear epitopes present in 
wild type envelope as the polyclonal rabbit sera to HIV envelope IIIB was able to detect 
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envelopes via western blot. Compared to Envgp120 monomers, Envgp140 trimers may expose 
binding and neutralizing epitopes that are present only in envelope’s quaternary state [220, 221].  
The monomeric gp140 subunits formed trimers (Figure 10) that have similar antigenic properties 
as wild-type Envgp160s, as demonstrated by attaching to human CD4. In addition, the monoclonal 
antibody b12 bound to each trimeric Envgp140.  The b12 antibody recognizes a conserved region 
on gp120 mapped to a discontinuous epitope overlapping the CD4 binding site [222]. Studies 
indicate that b12 monoclonal protect animals from viral challenge [223-225]. The results 
obtained with the consensus Env is this study was similar to that seen in previous consensus Env 
studies. Although antigenicity does not necessarily correlate to immunogenicity or efficacy, the 
presence of conserved epitopes indicates the possibility of the envelopes to induce a broadly 
reactive immune response. 
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5.0  SPECIFIC AIM II: TO DETERMINE THE VACCINE REGIMEN OF 
CONSENSUS ENVELOPES THAT WILL ELICIT THE HIGHEST ENVELOPE TITER 
TO HOMOLOGOUS VACCINE  
5.1 FOREWORD 
This chapter contains the results of experiments performed in Specific Aim II. The overall aim of 
this dissertation was to create an envelope vaccine capable of eliciting cross-binding antibodies 
to HIV-1 envelopes prior to viral challenge. Evaluating the immunogenicity of envelope trimers 
in a small animal model was essential before determining immunogenicity and efficacy in non-
human primates. In addition, the vaccine regimen chosen has been shown to influence immune 
response elicited by vaccination.  
 
5.2 ABSTRACT 
Vaccine regimen has been shown to influence the outcome of HIV envelopes immunogenicity 
and efficacy. In this aim, four regimens were compared: DNA prime/boost, DNA prime/ 
Envelope trimer boost, Envelope trimer prime/boost or VLP prime/boost.  To determine the most 
effective vaccine regimen to be used to evaluate all vaccines only the consensus M envelope was 
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used in the initial mice study. BALB/c mice were vaccinated at 0 and 3 weeks and sera were 
collected at week 5. Total IgG titer to the homologous antigen (consensus M) was used as the 
comparative measurement between the vaccines, and the regimen of Envelope trimer 
prime/boost was selected. In a follow up study mice were vaccinated via the Envelope trimer 
prime/boost regimen with either individual consensus antigens or a polyvalent mixture of 
consensus antigens (A, B, C, E). The antibodies elicited by vaccination did not differ in quantity 
or quality between envelope vaccines. Furthermore, the antibodies elicited reacted with not only 
the homologous vaccine antigen, but also binding breadth was extended to wild type envelope 
from multiple clades. 
5.3 INTRODUCTION 
In developing a vaccine capable of eliciting a protective antibody response to Env, two aspects 
need to be considered: the antigen design and the immunization regimen used to deliver the 
antigen. Antigen design was covered previously (chapter 4); therefore, this chapter focuses on 
immunization regimen selection and antigen immunogenicity in mice. A number of strategies 
have been implemented in an effort to elicit an effective antibody response by vaccination. These 
strategies are (i) subunit protein [226, 227], (ii) viral vectors [228, 229], (iii) DNA vaccines [230, 
231], (iv) viral vector plus protein [229], (v) DNA plus viral vector [97] and (vi) DNA plus 
protein [232]. After the STEP vaccine trial, concerns arose of potential vector enhancement of 
host susceptibility to HIV infection via immune activation [233].  Vaccine regimens with viral 
vectors were therefore not included as possible immunization regimens. The immunization 
regimens investigated were (i) DNA, (ii) DNA plus protein, and (iii) protein.  
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DNA only vaccination elicits specific antibody responses to HIV immunogens in animal 
studies and human clinical trials [230]. This success has been attributed to several positive 
aspects [234, 235]. First, the endogenous production and processing of the antigen allows for 
proper translation, native folding and normal post translational modifications. Secondly, the 
DNA is taken up by the cells at the site of vaccination making antigen production similar to live 
attenuated vaccines. Additionally, endogenous production of the antigen leads to efficient 
presentation to the immune system through class I and class II major histocompatibility 
complexes, thereby allowing for efficient T cell responses to the antigen. Lastly, unlike live-
attenuated vaccines, DNA vaccines are non-replicative and non-integrative which improves the 
safety. However, DNA vaccines have been shown to have low in vivo transfection efficiency 
even after enhancement of DNA constructs such as codon optimization and manipulation of 
leader sequences and promoters [236, 237]. Despite the limitations in vivo, DNA vaccinations 
are effective at priming the immune system. Hence, the use of combination vaccines is an 
effective option to improve on DNA vaccination. One of the simplest approaches to modulations 
of DNA vaccination is following DNA priming with a protein boost [238]. Protein boost of a 
DNA prime has been reported to elicit higher antibody titers than DNA alone. In addition, better  
neutralizing antibodies have been reported after boosting a DNA prime with oligomerized 
protein antigens [239].  The initial immunization vaccine regimen used to elicit antibodies to 
HIV was protein vaccination, which consisted of subunit Env vaccines. These vaccines showed a 
moderate level of protection in monkeys but failed in human clinical trials [91]. With the advent 
of trimerized Env antigens, the use of a protein-only vaccination has reemerged from the initial 
HIV clinical trials. Over the last five years, protein-only vaccinations have elicited immune 
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responses that provided some level of protection against both homologous and heterologous 
SHIV mucosal challenges [240, 241]. 
 Before the efficacy of any HIV vaccine can be investigated in the accepted model of 
monkeys, the immunogenicity is tested in small animals. Mice provide an in vivo model for 
which an antigen is characterized. Mice represent a less expensive animal model and the 
immunological tools are more readily available than in other rodents for investigating immune 
components.  After vaccination in mice, the regimen that proved to be superior based on IgG titer 
was the protein vaccination. Using this immunization regimen, all consensus antigens elicited 
similar antibody responses either individually or as a polyvalent vaccine mixture (Poly 
consensus), which included consensus envelopes A, B, C and E.  The only difference detected 
between the envelopes was the limited breadth of elicited anti-Env antibody respoenses by the 
consensus E Env: only three of the wild type envelopes were reactive. However, this limitation 
was not detected in the Poly consensus vaccine that will be used in the monkeys.  
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5.4 RESULTS 
 
 
 
Figure 13: Schematic of the mouse studies performed in this aim.  
The first mouse study was performed to determine the vaccine regimen that would elicit the highest 
total IgG to consensus M. The second study utilized the vaccine regimen chosen from study 1 (protein 
prime/boost) to evaluate the immunogenicity of all consensus vaccines and investigate whether 
combining the consensus envelopes reduce the immunogenicity of any individual envelope 
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5.4.1 Anti-Env responses between multiple vaccine regimens 
Env-specific total IgG titer was measured two weeks after the final vaccination (Figure 14). 
After two vaccinations, there was one responder above the endpoint titer of 1:100 in both DNA 
prime vaccine groups. There were no responders in the VLP vaccine group or any of the control 
groups. In contrast, all mice in the two Envgp140 trimer only groups responded with end point 
titers greater than 1:1000. There was no significant difference between the endpoint titers of the 
mice vaccinated with 1µg or 10µg of envelope (p-value 0.0295). Serum of animals with 
detectable envelope responses was used to determine the IgG subtypes profile via ELISA (Figure 
15). There was no difference in the pattern of IgG subtype elicited with either an Envgp140 trimer 
only regimen or a DNA only regimen. However, the DNA prime/Envgp140 trimer boost resulted in 
only an IgG1 subtype being elicited. 
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Figure 14 : Total IgG responses elicited to Consensus M 
Mice were vaccinated with either a regimen of DNA only, protein only or a combination of DNA and 
protein. Animals were given 2 vaccinations intramuscularly, prime at week 0 and boost at week 3 
and bled at week 5. Total IgG responses to homologous envelope were determined via ELISA to 
consensus M. The endpoint titer is described on the y–axis and the different vaccine regimens are 
described on the x-axis.  
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Figure 15 IgG subtypes elicited by various vaccine regimens 
The sera of mice with detectable IgG envelope specific titers were used to determine the IgG subtypes 
elicited by vaccination included IgG 1, 2a and 2b. ELISA plates were coated with consensus M 
envelope and mouse serum was added at a dilution of 1:100. Secondary antibodies to mouse IgG 
subtypes conjugated to horse radish peroxidase were then used to detect the various IgG subtypes 
present in the mouse serum. The OD450 reading is given on the y–axis and the different vaccine 
regimens are described on the x-axis. 
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5.4.2 All consensus envelopes are equally Immunogenic 
To verify the immunogenicity of all consensus envelopes prior to vaccinating non-human 
primates, purified consensus Envgp140 proteins were formulated with Imject® alum adjuvant and 
injected into BALB/c mice. Two weeks post the final vaccination, all mice vaccinated with 
primary consensus Envgp140 proteins representing clades A, B, C, and E elicited high titer 
antibodies that recognized all consensus envelopes (Figure 16A). Mice vaccinated with an equal 
mixture of primary consensus Envgp140 proteins (Poly Consensus) had similar anti-Env IgG titers 
against all four consensus Env antigens as mice vaccinated with Con M Envgp140 (Figure 16B).  
Mock vaccinated mice had no detectable anti-Env IgG responses. Investigation of antibody 
secreting cells showed similar numbers of cells secreting IgG after vaccination with either the 
Poly Consensus or Consensus M Env vaccines (Figure 17). All consensus Env vaccinations 
resulted in cross-binding antibody to a panel of wild-type Env proteins representing different 
clades of HIV-1 (Figure 18). There was no detectable difference in the number of wild type 
envelopes identified by any vaccine except by antibodies elicited by consensus E Envgp140. Sera 
of mice vaccinated with consensus E Envgp140 recognized only three of the 11 wild type 
envelopes: 6535 (clade B), ZM214 (clade C) and 93TH975 (clade E).  
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Figure 16: Mice seroconvert after vaccination with consensus vaccines 
BALB/c mice were vaccinated at 0 and 4 weeks with blood collected at day 14 after final vaccination. 
Vaccines were formulated 10µg of purified protein with Imject® alum and delivered 
intramuscularly.  Total IgG at week 6 was determined via ELISA for each vaccine group. Values 
represent the geometric mean titer (+95% confidence interval) of log2 transformed titers. A) 
Endpoint titers of animals vaccinated with individual clade consensus envelope trimers (A, B, C, E).  
B) Endpoint titers of animals vaccinated with group M consensus envelope trimer and polyvalent 
vaccine (equivalent amounts of clade consensus envelope trimers). The endpoint titer is described on 
the y–axis and the identified Envgp140 trimer antigen used as coating antigen is described on the x-
axis. 
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Figure 17: Similar number of Antibody Secreting (ASC) detected with consensus Env 
Mice splenocytes were used to evaluate the presence of ASC seven days after final vaccination. Plates 
preincubated overnight with the different envelopes proteins (A, B, C, E, and M) were loaded with 
single cell suspension of splenocytes. After 48 h incubation at 37 °C with a mouse IgG conjugated 
with horse radish peroxidase (HRP) antibody, the complex was detected using ImmPact NovaRED 
peroxidase substrate (NovaRED TM,Vector Labs, Burlingame, CA, USA.) to develop Antibody 
Secreting Cells specific to the envelope coated on the plate. These spots were then counted by the 
ImmunoSpot ELISPOT reader. The number of cells detected per 1x106 splenocytes on the y–axis and 
the identified Envgp140 trimer antigen used as coating antigen is described on the x-axis. 
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Figure 18. Consensus vaccines elicit cross-binding antibodies 
BALB/c mice were vaccinated at 0 and 4 weeks with blood collected at day 14 after final vaccination. 
Vaccines were formulated 10µg of purified protein with Imject® alum and delivered 
intramuscularly. Serum IgG was detected by allowing anti-Env antibodies to bind to primary gp120 
envelopes from either clades A, B, C and E. A positive titer was determined when the antisera 
detected the Env at a dilution that was 2X over the antisera collected from control, non-vaccinated 
animals. The OD450 reading is on the y–axis and the identified Envgp140 trimer antigen used as 
coating antigen is described on the x-axis. 
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5.5 DISCUSSION 
The multiple strategies used in this chapter have been performed by our group and others with 
various antigens including envelope [1, 240, 242]. However, the antigen influences the elicited 
antibody and there was a necessity to directly compare multiple immunization regimens using 
the synthetic consensus Envgp140 vaccines. The results from these studies identified the protein 
vaccination as the vaccine regimen that induced the highest total IgG Env responses. The protein 
vaccine induced the highest total IgG titer to homologous envelope and induced the same IgG 
subtype profile as DNA only vaccination. The IgG subtypes elicited by vaccination included IgG 
1, 2a and 2b. Mouse IgG 2a and 2b are potent inducers of antibody-dependent cellular 
cytotoxicity and complement-dependent cytotoxicity [243]. Active and passive immunization 
studies have implicated both of these functions as possible mechanisms by which antibodies 
mediate protection [224, 244, 245]. The presence of these IgG subtypes further supported the 
protein immunization regimen for the consensus Env antigens. The poor responses seen in the 
immunization regimen of DNA prime plus protein boost was not expected. The DNA used is the 
same plasmid used to produce the purified protein, hence it is known to express. The poor 
responses seen with DNA vaccination could be a result of the dose of DNA used and or the mode 
of DNA vaccination.  
The vaccines that are being considered for use in monkeys are the consensus M and the 
polyvalent consensus vaccines (A, B, C, and E). The monkey study was only powered to 
evaluate two vaccines and therefore the immunogenicity of individual consensus envelopes A, B, 
C, and E had to be evaluated in mice.  In addition, to ensure that one envelope is not significantly 
more immunogenic causing a bias of the elicited immune response, each Env antigen was 
evaluated individually and in combination as the intended polyvalent mixture. In addition, the 
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consensus Env antigens elicited broadly binding antibodies that reacted to a panel of wild type 
Envs. The wild type envelopes were chosen because they were transmitted mucosally, and the 
isolates used the CCR5 coreceptor. These features are key characteristics of viruses involve in 
transmission. The only Envgp140 vaccine that elicited a narrow anti-Env binding breadth was 
consensus E Envgp140, which detected only three of the eleven envelopes tested. However, the 
inclusion of consensus E Envgp140 protein in the polyvalent vaccine did not affect the breadth of 
the antibody responses elicited by vaccination. On the contrary, it supports the use of polyvalent 
mixtures as a strategy for broadening a vaccine’s immune responses beyond a single 
immunogen. The fact that the consensus E Env had the least amino acid identity with consensus 
M (~83%) may explain its limited envelope breadth to other clades. Using consensus M is the 
immunogen with the least diversity to primary HIV isolate envelopes consensus E was the most 
divergent from primary HIV isolate envelopes, especially across clades.  The results generated 
from vaccination in mice confirm the immunogenicity of the consensus Envgp140 trimer vaccines 
and allows for the evaluation of these vaccines for immunogenicity and protective efficacy in 
monkeys. The results also confirm the use of consensus antigens to broaden antibody responses 
as previously reported [128, 219]. 
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6.0  SPECIFIC AIM III: TO EVALUATE THE IMMUNOGENICITY AND 
EFFICACY OF THE CONSENSUS M AND POLY CONSENSUS VACCINES IN NON-
HUMAN PRIMATES  
6.1 FOREWORD 
With the absence of known correlates of protection for HIV, a vaccine’s efficacy can only be 
determined by challenge. In this chapter two vaccines are being evaluated for immunogenicity 
and efficacy in monkeys. The vaccine was designed in an effort to produce a breadth of cross-
clade binding envelope specific antibodies prior to challenge. Specific Aim III was design to 
address the question of vaccine efficacy and the results of this aim is covered in the following 
chapter. The accepted model to determine vaccine efficacy is the non-human primate, therefore 
this is the animal model being used..  
6.2 ABSTARCT 
The development of a preventative HIV/AIDS vaccine is challenging due to the diversity of viral 
genome sequences, especially in the viral envelope. Since it is not possible to directly match the 
vaccine strain to the vast number of circulating HIV-1 strains, it is necessary to develop an HIV-
1 vaccine that can protect against a heterologous viral challenge. Previous studies from our group 
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demonstrated that a mixture of wild type clade B Envs were able to protect against a 
heterologous clade B challenge more effectively than a consensus clade B Env vaccine.  In order 
to broaden the immune response to other clades of HIV, in this study rhesus macaques were 
vaccinated with a polyvalent mixture of purified HIV-1 trimerized consensus Envgp140 proteins 
representing clades A, B, C, and E.  The elicited immune responses were compared to a single 
consensus envelope representing all isolates in group M (Con M). Both vaccines elicited anti-
envelope IgG antibodies that bound an equal number of HIV-1 Envs representing clades A, B 
and C. In addition, both vaccines elicited antibodies that neutralized the HIV-1SF162 isolate.  
However, the vaccinated monkeys were not protected against SHIVSF162p4 challenge.   These 
results indicate that consensus envelope vaccines, administered as purified Env trimmers, elicit 
antibodies that bind to Envs from strains representing multiple clades of HIV-1, but these 
vaccines did not protect against heterologous SHIV challenge. 
6.3 INTRODUCTION 
Human Immunodeficiency Virus (HIV)/Acquire Immunodeficiency Syndrome (AIDS) have 
been a global public health issue for ~30 years. The World Health Organization (WHO) in 2011 
reported 2.7 million new HIV infections with 34 million people living with the virus worldwide 
[5]. Despite the effectiveness of highly active anti-retroviral therapy (HAART) [246], a long 
time goal to solving the AIDS crisis is an effective vaccine [247]. One of the greatest struggles 
for developing a preventative HIV vaccine is overcoming the diversity of viral isolates [248].  
The envelope sequences can differ up to 35% between clades and ~15% within a specific clade 
[249]. Viruses classified as clade B are responsible for >40% of infections in the Americas and 
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Europe, but in Asia and sub-Saharan Africa, where most new infections are recorded each year, 
other clades are dominant. Most new infections in these regions are classified as clades A, C, or 
A/E viruses [250, 251].  Any HIV vaccine that will prevent infection must be able to overcome 
the diversity of HIV sequences. 
Two strategies that have been used in vaccine design to overcome the HIV sequence 
diversity are polyvalent mixtures and consensus antigens [104, 252-254]. Polyvalent vaccines 
increase breadth by including several epitopes by adding multiple copies of a target(s) into a 
single formula. Polyvalent vaccine strategies have been employed to increase the breadth of the 
humoral and cellular immune responses [200, 255].  Previous publications with polyvalent 
mixtures of envelopes or HIV proteins (Gag-Pol, Tat and trimeric envelope) reported a degree of 
protection against heterologous challenge [200, 241].  Another strategy uses consensus antigens 
as immunogens.  These vaccines rely on a centralized antigen designed to reduce sequence 
diversity by using the most common amino acid at each position of the protein. Consensus 
vaccines are designed to reduce the genetic differences between the vaccine and the primary 
isolate. Consensus antigens have been shown by our lab and others to increase the breadth of 
immune responses [135, 256-258]. Previously, our laboratory compared the ability of a 
consensus clade B (ConB) Env VLP vaccine and a polyvalent clade B (PolyB) Env VLP vaccine 
to  protected rhesus macaques against a vaginal SHIVSF162p4 challenge [200]. However, there 
were undetectable levels of anti-Env IgG or neutralizing titers in these vaccinated animals prior 
to challenge. 
In this study to overcome the diversity in envelope sequences and to design a more 
effective AIDS vaccine, consensus envelope sequences were designed for 4 clades of HIV-1 (A, 
B, C, and E), as well as a single consensus Env representing isolates from all of Group M.  For 
 91 
the first time in the same study consensus Env sequences were used in a polyvalent vaccine 
mixture, and compared to a Con M Env, to assess the ability to elicit a broadly reactive anti-Env 
immune response. To elicited immune responses to Env prior to challenge, rhesus macaques 
were vaccinated with trimerized consensus Envgp140 immunogens in a either polyvalent mixture 
representing clades each of the 4 clades or as a single consensus M envelope. The immunological 
responses of the polyvalent mixture were compared to that of the single Con M Envgp140 vaccine.  
Even though both vaccines elicited a broader anti-Env immune responses against multiple clades 
of HIV, however, neither vaccine strategy efficiently protected monkeys against a SHIVSF162p4 
challenge.    
6.4 RESULTS 
6.4.1 Vaccination of Non-Human Primates with Consensus Envelopes 
To determine the ability of the vaccines to induce a protective response in non-human primates, 
rhesus macaques were vaccinated with either Con M or the polyvalent consensus mixture. 
Monkeys were administered 3 vaccinations of Envgp140 formulated with Imject® alum adjuvant. 
Mock vaccinated monkeys were administered PBS formulated with adjuvant (Table 4) Monkeys 
vaccinated with Con M or polyvalent consensus had anti-Env antibody titers greater than 1:400 
against all consensus envelopes following the three vaccinations (Fig. 19A).  Collected sera were 
tested for the ability to bind to a set of primary envelopes representing clades A, B, C, and E 
(Table 5).  These diverse R5-tropic envelopes represent viruses were isolated from individuals 
located in different areas of the world following various modes of transmission. Most of the 
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viruses were isolated within a few weeks of transmission. The diversity of the envelopes chosen, 
as well as their similarity to the consensus envelopes, is displayed in the phylogenetic tree where 
envelopes cluster into their identified clades (Fig. 19B). Also, the consensus envelopes clustered 
with the envelopes from their representative clades. The consensus M did not cluster with any 
one clade, but as expected, was located in a more central position on the tree.  
Both Con M and polyvalent consensus Envgp140 vaccines elicited anti-Env antibodies 
that recognized envelopes from clade A, B and C. However, the envelopes SC42, THRO4, 
PVO4, (clade B), DU172 (clade C) and 93TH975 (clade E) were not significantly recognized by 
sera collected from vaccinated animals (Fig. 19C). Overall, there was no binding preference of 
the elicited anti-Env antibodies to primary envelopes based on clade, location, or year of 
envelope isolation.  
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Table 4: Vaccine Groups and Vaccine given 
Each animal was vaccinated 3 times week 0, 4 and 8. Each vaccine was given in combination alum 
imject© as an adjuvant. The table gives the vaccine groups, the identification number of animals in 
each group and the vaccine and treatment (in the case of group 3) received by the animals 
 
 
 
Vaccine Group Animal Numbers Vaccine Given Other Treatment
Group 1 N1,N2,N3,N4 Adjuvant only
Group 2 P1,P2,P3,P4 Mixture of  consensus 
A,B,C,E Env gp140
Group 3 M1,M2,M3,M4 Consensus M Env gp140 Depletion of  CD8+ T cells
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Table 5: Information of envelopes used for assays: 
 Primary envelopes from various clade was chosen based to have a diversity of locations and mode of 
mucosal transmission. Envelopes were used to test the presence of binding and neutralizing 
antibodies elicited by vaccination of consensus vaccines in non-human primates. SF162 was included 
because it is the challenge virus envelope 
 
 
 
 
 
 
 
 
Env ID Clade Location
Mode of 
Transmission
Length of 
Infection Mo/yr isolated Coreceptor
Du172.17 C South Africa M-F 12 weeks Nov-98 R5
ZM214M.PL15 C Zambia F-M <13 weeks Jul-03 R5
CAP210.2.00.E8 C South Africa M-F 5 weeks May-05 R5
CHN19 C China R5
HIV16936-2__EF117270 C India F-M 1 week Nov-00 R5
Q168.ENV.B23 A Kenya M-F 1week R5
Q461.ENV.C2 A Kenya M-F 4 weeks R5
HIV env 6535 clone 3 B USA M-M 6 weeks Mar-95 R5
PVO clone 4 B Italy M-M 4 weeks Jan-96 R5
pRHPA 4259 clone7 B USA M-F <8 weeks Dec-00 R5
pTHRO4156 clone 18 B USA M-M 1 week Aug-00 R5
SC 422661.8 B Trinidad F-M 4 weeks Jan-95 R5
SF162 B USA R5
93TH975-15 E Haiti F-M <18 weeks Jan-93 R5
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Figure 19: Binding breadth of vaccinated NHPs sera.  
NHP were vaccinated at weeks 0, 4 and 8 with blood collected 14 days after each vaccination. Vaccines were formulated with 
300µg of purified protein and Imject® alum and delivered intramuscularly. A) Sera collected on day 35 were used to determine 
total IgG via ELISA for each vaccine group. Bar values represent the geometric mean titer (+95% confidence interval) of log2 
transformed titers. The endpoint titer is described on the y–axis and the identified Envgp140 trimer antigen is described on the 
x-axis.  B) The unrooted phylogenetic tree was produced using Phylogeny.fr web service and the 14 HIV-1 envelope sequences 
based upon the list of envelopes in table 5 showing.  The envelopes were from clades A, B, C, E from 1993-2005. The clades are 
indicated on the tree and the consensus envelopes are circled. C) At day 35 post-vaccination, anti-Env IgG was detected in the 
serum samples (1:100 dilution) against a panel of primary Envgp120s from clades A, B, C and E via ELISA. Bar values represent 
the geometric mean titer (95% confidence interval) at an OD450. The OD450 values are displayed on the y-axis and the 
Envgp120s used are listed on the x-axis. A two-way ANOVA with Bonferroni’s post-test was used to evaluate Statistical 
significance between the vaccines for each test antigen. A p-value of less than 0.05 was considered significant. Significant seen is 
in relation to mock vaccinated animals. 
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6.4.2 Responses to Challenge Envelope SF162 
At 2 weeks after final vaccination (day -14 prior to challenge), anti-EnvSF162 IgG antibodies were 
detected in monkeys vaccinated with either vaccine (Fig. 19C).  In addition, these antibodies 
were able to neutralize the ability of HIVSF162 to infect cells in vitro (Fig. 20A).  All vaccinated 
monkeys had a neutralizing titer of 1:40, except for monkey M4 that had a titer of 1:320. Two 
weeks following challenge, only monkey P4 had an increase in neutralizing titers.  There were 
detectable neutralization titers in 3 of the 4 mock vaccinated monkeys two weeks post-challenge 
(Fig. 20A). No monkey had antibodies that recognized a set of overlapping SF162 envelope 
peptides. These pools of peptides represented the SF162 Env regions V1/V2, V1 only, or V2 
only (data not shown).  Interestingly, there was no detectable INF-γ envelope or gag-specific T-
cell responses prior to challenge or 7 days post-challenge.  At day 14 post-challenge, monkeys 
vaccinated with the polyvalent consensus vaccine had higher number of T cell response 
compared to monkeys vaccinated with Con M vaccine (Fig. 20B).  However, differences in 
number of T cell responses between the animal groups were not significant difference. 
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Figure 20 Neutralizing titers to the SF162 envelope and post challenge cellular responses.  
A) Neutralization of HIVSF162 by serum collected at day 21 and 35 post-vaccination and 14 post-challenge.  The 
sera dilution at which 50% of virus infection is inhibited is displayed on the y-axis.  Neutralizing titers for 
individuals monkeys are listed on the x-axis by each vaccine group.  B) INF-γ ELISPOTs were performed using 
monkey PBMCs collected 14 (left panel) and 21 (right panel) days post-challenge. 1x105 PBMCs were 
stimulated with 30ug of Gag peptide pools representing SIVmac239 or Env pools representing either Consensus M 
or SF162p3 (overlapping peptides, 15-mers with11 amino acid overlap NIH AIDS Research and Reference 
Reagent program. Spot forming units (SFU) per one million PBMCs are listed on the y-axis and the peptide 
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6.4.3 SHIVSF162 challenge  
To evaluate the protective efficacy of each vaccine, monkeys were challenged rectally 
four weeks after final vaccination with SHIVSF162p4 (640TCID50). All mock vaccinated and 
polyvalent consensus vaccinated monkeys were infected following challenge (Fig. 21A and B). 
Viral loads peaked at day 14 post-challenge at ~1 X 10^6 RNA copies/ml and then declined to 
undetectable levels between days 40-80 post-infection.  Two out of fours monkeys (M1 and M4) 
vaccinated with Con M vaccine had no detectable virus at any time point post-challenge (Fig. 
21C).    Monkeys M2 and M3 had a similar viral pattern as mock vaccinated monkeys with a 
peak at day 14, followed by a rapid decline. 
To determine whether Con M vaccinated monkeys completely sterilized infection, at day 
70 post-challenge all Con M vaccinated monkeys were depleted of CD8+ cells by administering 
monoclonal antibody M-T807R1 intravenously [245]. Seven days following antibody 
administration, no CD8+ cells were detected in the peripheral blood that was sustained for an 
additional 18 days (Fig. 22A).  Previously infected monkeys M2 and M3 had a re-emergence of 
virus during this CD8+-depletion period (Fig. 22B). Monkey M4 who was initially averimic after 
challenge had an emergence of virus after CD8+-depletion. In contrast, monkey M1 maintained 
undetectable viral loads following CD8+ depletion. 
 
 
 
 
 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 SHIVSF162 virus challenge:  
 Monkeys were challenged rectally with 640 TCID50 SHIV SF162p4 at week 12 post initial vaccination. Viral 
titers were determined from collected sera. Viral titers for each individual monkey are displayed as RNA 
copies/ml of blood on the y-axis by days post challenge on the x-axis. A) Mock vaccinated animals (Imject© 
adjuvant only).  B) Polyvalent Consensus Envgp140 vaccine C) Consensus M Envgp140 vaccine. 
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Figure 22 Confirming Vaccine efficacy 
Animals vaccinated with consensus M Envgp140 were all depleted of CD8+ cells by administering the M-
T807R1 antibody subcutaneously (50mg/Kg) at day 0 (day 70 post challenge). A) Number of CD8+ cells 
following antibody administration over the 25 day period of observation. B) Viral titers for each individual 
monkey are displayed as RNA copies/ml of blood on the y-axis by days post challenge on the x-axis. 
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6.5 DISCUSSION 
HIV-1 envelope only vaccines have been used effectively to protect monkeys against a 
homologous SHIV challenges [259, 260]. Our hypothesis put forth in this study was to design an 
envelope based vaccine to elicit broadly reactive antibody responses to multiple envelopes 
representing different clades of HIV-1 and to protect against a virus with a heterologous 
envelope to the challenge virus.  For real-world situations in humans, the ability to match the 
gene sequences used in the vaccine to the possible exposure virus is not possible.  Therefore, 
studies that use a matched envelope in the vaccine to the challenge strain is appropriate for 
proof-of concept studies, but our group set a more challenging goal to protect against a challenge 
virus with a mismatched vaccine with a limited number of vaccinations.  We report here that 
each consensus sequence representing clade A, B, C, E, in a polyvalent mixture or as a single 
consensus envelope representing the entire Group M elicited anti-Env antibodies that bound to a 
broad panel of HIV-1 envelopes.  However, the elicited immunity did not prevent infection by 
SHIVSF162p4. 
We chose to use a centralized vaccine approach to elicit an immune response that would 
recognize as many isolates of HIV-1 across various clades.  In previous studies, consensus 
sequences designed for clades B and C gag and envelopes elicited increased breadth of humoral 
and cellular immune responses [128, 257, 261, 262]. Consensus envelope sequences representing 
Group M, termed CON-S, elicited antibodies that neutralized multiple envelopes, as well as 
eliciting cross-clade cellular immune responses [135, 258]. However, viral challenges of CON-S 
vaccinated monkeys were not reported and therefore the efficacy of the induced immune 
response elicited by these vaccines is unknown.  
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Following three intramuscular vaccinations, all monkeys seroconverted by day 14 
following the final vaccination. The anti-Env antibody responses detected after vaccination were 
similar in both vaccine groups.  Nonetheless, there were differences in the vaccine efficacy 
following challenge between the two vaccine groups. Both non-neutralizing and neutralizing 
antibodies have been implicated in reducing rates of infection by HIV-1 [263, 264]. During the 
AIDS Vaccine 2011 conference, a report based on the analysis of the sera samples of vaccinated 
volunteers in the RV144 clinical trial stated that the vaccine elicited antibodies against the V2 
region of the HIV-1 envelope were correlated with lower rates of HIV infection [265]. Antisera 
collected from these vaccinated individuals did not neutralize the infection in vitro.  
Additionally, vaccine induced protection against a neutralization resistant virus in macaques was 
correlated with antibodies to the V2 region of Env [262]. Whether antibodies that bind to the V2 
region are correlated with protection against SHIVSF162p4 infection in this study is unclear.  There 
were no antibodies elicited in monkeys vaccinated with Con M or polyvalent consensus Envgp140 
vaccines that recognized SF162 Env linear peptides, including those specific to V2 (data not 
shown).  Further studies are necessary to determine if the two protected animals in the Con M 
Envgp140 group elicited antibodies recognizing conformational epitopes, such as the V1/V2 
scaffold proteins. These epitopes have been used to analyze human sera collected from 
vaccinated volunteers in the RV144 clinical trial [266]. Determining if antibodies specific to 
various conformational epitopes on envelope may explain the differences observed in vaccinated 
animals following SHIV challenge. 
Monkeys vaccinated with either polyvalent consensus or Con M Envgp140 trimers had 
neutralizing titers to HIV-1SF162. Neutralizing antibodies against envelope can protect monkeys 
against viral challenge [244] [240].  However, only one monkey (M4) in the present study had 
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high neutralizing antibodies (1:320) against SHIVSF162p4 that correlated with an undetectable 
viral titer 14 days after challenge.  However, following CD8+ T cell depletion, virus was 
detected (<1x105 RNA copies /ml) in the blood indicating that infection was not blocked, but 
may have been controlled by the vaccine elicited antibodies. T cell responses did not appear to 
play a role in protecting the monkeys from infection.  There was no difference in the number or 
kinetics in the elicitation of Env or Gag specific IFNγ producing cells following challenge in any 
of the vaccinated monkeys compared to mock vaccinated animals.  
In contrast to monkey M4, no virus was detected in the plasma of monkey M1 even after 
depletion of CD8+ T cells. Both IFNγ specific T cells and neutralizing antibodies were detected, 
but it is unclear whether immune responses may have contributed to the protection.  Monkey M1 
had a Mamu-B*008 MHC class I haplotype, which has been associated with control of SIVmac239 
virus; the parent virus of the challenge SHIVSF162p4 [267].  Therefore, a combination of the 
neutralizing antibodies, non-neutralizing antibodies and the Mamu-B*008 MHC class I 
haplotype may have resulted in “sterilizing” protection after viral challenge. However, the 
Mamu-B*008 MHC class I haplotype was also present in monkey M3, which had similar 
binding and neutralizing antibody titers as monkey M1, but was not protected from SHIV 
infection.  Even though no viremia was ever detected in monkey M4, it is possible that virus 
could be located in reservoirs, such as the bone marrow or gut mucosa [268]. The M-T807R1 
monoclonal antibody used for CD8+ T cell depletion is specific for cells in the serum and lymph 
nodes [269], therefore, it may have not depleted cells in reservoirs of hidden virus.   
Monkey M4 had neutralizing titers above 1:100 present during pre and post viral 
challenge, that contributed to reduced viremia and this lends credence to the possibility that a 
more robust antibody response could have resulted in better protection. Enhancement of the 
 104 
antibody response could have been accomplished with a better adjuvant. In this study, we used 
Imject® (Pearce, Rockford, IL, USA) as an adjuvant, but it recently has been shown that Imject® 
Alum is actually an amorphous aluminum hydroxycarbonate and is distinct from the aluminum-
containing adjuvants that are used in licensed vaccines [270]. While this adjuvant is effective at 
enhancing antibody titers when combined with a vaccine protein, the use of a combination 
adjuvant e.g. TLR agonist and alum may have resulted in a better immune response [271]. The 
use of AS04 a combination of TLR4 agonist and alum salt induces improved vaccine specific 
antibodies and B cell responses than alum alone [272]. While Env only vaccines have been 
successful against homologous challenge, both the human RV144 trial and monkey studies that 
resulted in significant protection from heterologous challenged, included other HIV protein 
components [200, 241, 273]. Including Tat in the vaccine formulation induces strong and 
persistent CD4+ T cells [274] and broadens T cell responses directed against Gag and Env [275, 
276]. Gag is known for inducing strong cellular responses that may lead to reduced viral loads 
[277, 278]. Addition of Gag and/or Tat to our Con M vaccine may have prevented infection or 
controlled undetectable virus in vaccinated animals more effectively than Con M Env alone.  
In conclusion, rhesus macaques were vaccinated with trimerized Envgp140 proteins 
representing consensus sequences for clade A, B, C, E, in a polyvalent mixture or as a single 
consensus envelope representing the entire Group M.  These consensus envelopes elicited 
antibodies with cross-clade anti-Env binding against a panel of HIV-1 Envs. However, this 
breadth of antibody binding to HIV-1 Envs did not correlate with the preventing infection by 
SHIVSF162p4. 
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7.0  SUMMARY AND DISCUSSION 
7.1 SUMMARY OVERVIEW  
The percentage of the world’s population infected with HIV has stabilized over the years [279]. 
However, the number of people infected with HIV has steadily increased due to new infections, 
life extending treatments for HIV infection, and the number of new infections outnumbering the 
number of AIDS-related deaths. Although the disease burden of HIV is disproportionate in 
developing countries, particularly in southern Africa, the epidemic does not only affect these 
regions [280, 281]. The District of Columbia in the USA reported more cases of AIDS per 
100,000 population in 2006 than were reported in many African countries [282]. In an effort to 
reduce the HIV global burden, multiple preventative measures are being investigated including 
education, male circumcision, and developing HIV vaccines. Vaccines have been instrumental in 
eradicating and reducing the global disease burden of multiple infectious agents such as small 
pox and polio [283]. Therefore, it is not surprising that the global health sector believes an 
effective HIV vaccine would be a great tool in the fight against HIV. 
Since 1987, many HIV-1 vaccines have been evaluated in monkeys, with over 30 of these 
vaccines entering human trials either in combination (eg. RV144 human trial combine the 
AIDSVAX and ALVAC vaccines) or alone [284, 285].  These vaccines had varying degrees of 
protection in monkeys, however only one human vaccine trial, RV144 (Thailand study), resulted 
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in significant protection (31%)[69]. The principles guiding the development of an effective HIV 
vaccine (in addition to safety) is the ability of the vaccine to induce HIV-1 neutralizing 
antibodies and/or HIV-1 specific CD8+ T cells [286]. Due to the rapid destruction of the immune 
system upon HIV infection, studies of acute infection have emphasized the need for a protective 
response to be present before HIV-1 transmission [287, 288].  
Studies have reported that antibodies directed at Env are capable of blocking infection 
and have been linked to reduced acquisition of virus [289]. In addition Env antibodies can also 
mediate antibody-dependent cellular cytotoxicity (ADCC) by binding to infected cells mediating 
cytolytic immune responses. These ADCC responses are cross-reactive and therefore can target 
diverse circulating HIV-1 strains [290, 291].  Other proposed non-neutralizing antibody activity 
includes complement, and endocytosis and degradation of opsonize HIV viral particles at the 
mucosal surfaces [292, 293]. Due to its extensive genetic variability and high tolerance for 
mutation, HIV has a substantial advantage for immune evasion and viral persistence. As a 
consequence of these properties, significant viral evolution occurs under immune pressure, 
which has lead to an epidemic fueled by a plethora of genetic variants [206, 294]. The substantial 
antigenic diversity of HIV-1 combined with the high glycoslation of gp120 and structurally 
imposed steric constraints of potentially neutralizing epitopes on Env has made developing an 
effective preventative vaccine a challenge [295-298]. The goal of this project was twofold: first, 
to develop an HIV-1 envelope vaccine capable of inducing cross-reactive antibody responses 
prior to infection; and second, to investigate whether the induced antibodies were sufficient to 
prevent infection in an NHP animal model. Prior to this work being done it was reported that 
consensus antigens, including Env, increased the breadth of responses when compared to a single 
primary envelope [105, 299]. In addition, our lab showed that a polyvalent mixture of primary 
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clade B Envs were able to protect from a clade B SHIV challenge [300]. The studies detailed in 
this dissertation expanded on the results of the previous work and investigated whether a single 
group M vaccine would result in protection from the same clade B SHIV. Additionally, the study 
was designed to induce envelope response prior to challenge, as no envelope responses were 
observed prior to challenge in the previous work. This is an important difference because of the 
requirement for circulating antibody during challenge in order to prevent infection, and the 
presence of detectable envelope responses prior to challenge may aid in identifying a correlate of 
protection from infection. The results reported in this dissertation did address the goals of the 
project.  Observations from the project demonstrated that both group M consensus Env vaccines 
(Con M and Polyvalent consensus) elicited pre-challenge antibody titers to a diverse panel of 
Env proteins from clades A, B and C. In addition two of four animals vaccinated with the Con M 
Env gp140 resulted in some level of protection, either no infection or reduced viral load after 
heterologous challenge. 
7.2 ANTIGENICITY OF CONSENSUS TRIMERS 
The work presented in this dissertation resulted in the development of five consensus envelope 
immunogens. The modified consensus sequences (A, B, C, E, M) resulted in glycoproteins that 
formed trimers. The individual gp140 monomers were in a confirmation that allowed for Env 
trimers to bind to CD4 (HIV envelope receptor) and associate with b12 monoclonal antibody (a 
well-documented cross-reactive HIV envelope antibody). These results indicated the 
conservation of functional and antigenic characteristics between the consensus envelopes and 
wild type HIV envelopes and imply correct structure of the synthetic antigens. The goal of using 
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the consensus strategy is to capture conserved antigenic epitopes in a population of sequences. 
Although other consensus envelopes have been shown to retain wild type characteristics, the 
synthetic nature of the envelope sequences requires that each envelope be evaluated for known 
antigenic epitopes.  The initial investigation into the conserved antigenic epitopes has since 
expanded into a collaborative study. In the collaborative study, all consensus trimers as well as 
primary isolates from various years (YU2, R2, ADA, PVO4 and SC42) are being mapped using a 
collection of mAb including recently isolated quaternary mAb. Quaternary antibodies recognize 
an epitope formed on the assembled envelope trimer (the quaternary structure of the molecule). 
A better understanding of the presence or absence of the contact surfaces of these Ab on the 
various envelopes would aid in correlating the protection outcomes to known conserved 
epitopes. Also, the results from epitope mapping will improve on the current structure-based 
vaccine design.  
The presence of broadly neutralizing antibodies isolated from infected individuals 
demonstrates the proof–of–concept that neutralizing antibodies to conserved regions can be 
elicited.  The use of CD4 and mAb b12 to determine conserved antigenic epitopes is important, 
as the antibodies that bind to these functional epitopes have been shown to neutralize a diverse 
panel of HIV-1 viruses.  For example, mAb b12 has been shown to neutralize up to 75% of B 
strains and up to 50% of non-B strains [301]. Epitope mapping of prior consensus envelopes was 
done using broadly neutralizing mAb. However, until recently (2010-11) the only available 
broadly neutralizing mAbs were isolated from people infected with clade B viruses and some 
have been shown to be polyreactive (b12, 2G12, 2F, 17b). To expand on the knowledge of the 
full repertoire of HIV-1 neutralization epitopes, the isolation of new mAbs from non-B infected 
individuals has been under investigation. These investigations have led to the isolation of new 
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mAb such as VRCO1, PG9 and PG16. Some of the new antibodies are categorized as quaternary 
mAb and have been shown to recognize complex epitopes formed by the interactions of the 
envelope trimer [302, 303].   
  The epitope mapping of the five consensus envelope trimers constructed in this 
project included older mAb b12, 17b, and 2G12 as well as more recent quaternary mAb VRCO1, 
PG9 and PG16. Thus far in the investigation, differences between consensus envelopes were 
found with mAbs b12, 17b and PG9. Consensus B dissociated at a slower rate from b12 than the 
other envelopes and was able to bind to 17b prior to CD4 binding. 17b’s conserved antigenic 
epitope is exposed upon CD4 binding [304]. However, in the case of consensus B, Env-CD4 
binding was not required for 17b binding (data not shown). These differences indicate that the 
confirmation of the receptor and co-receptor binding sites of consensus B envelope trimer are 
different from that present in the other envelopes tested. These differences may have contributed 
to the lack of protection and limited envelope breadth seen in our lab’s previous study where 
Consensus B VLPs were used for vaccination [300]. In this study, the limited breadth of 
consensus B was addressed by adding other clade consensus Envs to the vaccine. The breadth of 
antibodies elicited by the polyvalent consensus envelope vaccine from other clades was increase 
compared to the consensus B only vaccine. This increase in breadth by combining multiple 
consensus envelopes is being reported for the first time. However, the proof-of concept of 
multiple envelopes increasing antibody breadth had been done using multiple primary envelopes 
[257, 305]. The work reported in this dissertation has provided evidence that the same outcome 
could be achieved by a mixture of clade consensus envelopes, eliminating the issue of 
determining which primary envelopes to use in the polyvalent vaccine. Instead of one envelope 
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isolate being chosen, all candidate envelope isolates could be used to determine a consensus 
clade envelope to then use in a polyvalent vaccine.  
Epitope mapping of the consensus envelopes with recently identified and characterized 
quaternary monoclonal antibodies (PG9) [306-308] have also demonstrated differences between 
the envelopes. These antibodies were first isolated from individuals infected with viruses from 
clade A. PG9 has been shown to bind to glycans associated with the V1/V2 region of Env gp120 
[307] and antibodies elicited in the V1/V2 region of Env have been implicated as a correlate of 
reduced infection in the RV144 Thailand study [69]. The PG9 monoclonal antibody binds to 
Consensus M and A trimers only. The PG9 antibody was isolated from an individual infected 
with a clade A virus [309]. Therefore, it is not surprising that the consensus A envelope was 
recognized by the antibody. The binding of PG9 to HIV-1 envelopes is influenced by subtle 
differences in loop length, spatial orientation of glycan residues and the net charge of β sheet C 
region that directly binds to PG9 CDRH3 within V2 loop. In initial screening of the consensus 
envelopes there was no significant difference in the length of the V2 loop and glycosylation sites. 
However, spatial orientation of glycan residues may play a role in the absence of PG9 binding to 
consensus Envs B, C, and E. The inclusion of clade A sequences into the consensus M resulted 
in the inclusion of PG9 binding site. The amount of PG9 epitope present in the polyvalent 
vaccine is at least 25% less than its presence in the Consensus M vaccine. The binding of PG9 to 
consensus A and M provides evidence that these envelopes could elicit similar antibodies. The 
differences in the amount/concentration of the PG9 epitope presence in the two vaccines may 
explain the difference observed after challenge between the two groups.  
Identifying where the vaccine elicited antibodies bound to the antigen would add to the 
information already gathered from this project about the epitopes, structure and protective 
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efficacy of antibodies. Experiments could be designed to isolate cross-reactive mAbs from 
vaccinated NHP and would then be used to identify their antigenic epitopes. This would address 
the question of whether different antibodies to different epitopes were elicited by the two 
vaccines. Given the differences being observed in the epitope mapping study and the 
immunological results in this project, differences would be expected. Two possible scenarios that 
may be identified 1) Same antibodies in all vaccinated animals, but protected animals have a 
higher concentration of antibodies that bind to conserve epitopes (such as CD4 binding site) 
compared to unprotected animals 2) Differences in antibodies: protected vaccinated animals have 
antibodies that bound to multiple epitopes compared to unprotected animals. In a natural 
infection, the ability to induce a protective response against a virus is due to polyclonal 
antibodies. These polyclonal antibodies directed at multiple different epitopes act in synergy to 
inactivate the virus. In addition, the project may discover yet unknown viral epitopes targeted by 
cross-reactive antibodies which would lead to a better understanding of current structure based 
design. 
7.3 IMMUNOGENICITY AND EFFICACY 
  It is well known that antigenicity and immunogenicity are not inter-changeable, therefore 
it was necessary to evaluate the immunogenicity of consensus envelopes. Animal vaccination 
with the consensus envelopes induced antibodies able to detect multiple envelopes from clades 
A, B, C and E. Non-human primate vaccination also resulted in detectable neutralizing 
antibodies to the challenge envelope SF162 in vitro.  The induction of cross-reactive antibodies 
has been shown with Consensus M in small animals and with polyvalent primary envelopes. This 
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is the first time that this envelope cross-reactivity has been shown using a polyvalent consensus 
Env only vaccine.  Furthermore, the broadly reactive antibody response was observed in both 
small animal and NHP models.  The study directly compared a single group M envelope vaccine 
and a polyvalent group M vaccine and showed that there was no significant difference in the 
breadth of the elicited response. By comparing a group M consensus Env to a polyvalent mixture 
of consensus Env antigens, we stringently evaluated the breadth of vaccine-induced antibody 
responses. Previous studies have only compared a consensus group M Env to a single primary 
envelope in the same study and reported greater antibody and T cell breadth with consensus 
group M Env. The breadth of a mixture of 5 Env isolates from different clades (A, B, C) and a 
single Gag was also investigated and shown to be superior to the use of a single Env isolate 
[305]. Additionally, our finding that a polyvalent mixture did not improve antibody breadth is 
noteworthy because a single immunogen (group M) would be easier and more economical to 
manufacture. However, a major pitfall of this study was the limitation of the neutralization 
breadth.  
Neutralizing antibodies are known to completely block HIV in animal model [310], 
maternal NAb aid in protection against perinatal transmission  [311, 312] and evidence has 
suggest that they might protect from superinfection [313]. The presence of broadly neutralizing 
antibodies in infected individuals is infrequent [314, 315] and studies of their structure and 
phenotype of these antibodies demonstrate unusual features. These unusual features and low 
frequency suggest that the mAb arose from atypical B-cell induction pathways. For example, 
2F5 and 4E10 have been reported to be self-reactive, and b12 has an unusually long third 
complementarity determining region of antibody heavy chains (CDRH3) for a mAb [316, 317]. 
This CDRH3 allows b12 to overcome the steric hindrance that protects the envelope’s receptor 
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binding pocket from neutralizing antibodies [317]. These observations have brought to 
realization that understanding envelope antibody affinity maturation may have a greater impact 
on vaccine design [318]. It is known that broadly neutralizing mAbs demonstrate moderate to 
high levels of affinity maturation and may require repeated antigen stimulation. This need for 
constant antigen stimulation may be why broadly neutralizing mAbs occur in patients who are 
infected for several years or more. Strategies which could be used to facilitate antibody affinity 
maturation include 1) use of adjuvants that lead to the induction of cytokines for better germinal 
centers, and 2) multiple boosts or alternate platforms that provide antigen stimulation for 
prolonged periods.   
In this project, the adjuvant Imject alum was used to help with the induction of cross-
reactive antibodies. This adjuvant was successful when used in another study performed in the 
lab using a consensus influenza envelope vaccine COBRA [209]. The limited success  (low IgG 
titers and limited neutralizing breadth) in this project could be attributed to the recent findings 
that Imject® Alum is actually an amorphous aluminum hydroxycarbonate and is distinct from the 
aluminum-containing adjuvants that are used in licensed vaccines [319]. Imject® Alum 
formulation of amorphous aluminum hydroxycarbonate and crystalline magnesium hydroxide is 
similar that that seen in Maalox antacid. Such chemical differences might be critical to the 
outcome of the immune response [320]. Licensed alum has been shown to activate NLRP3 
inflammasome. Several particulate materials activate the NLRP3 inflammasome in a similar 
way, and physico-chemical properties are key. For example, although Monosodium urate or uric 
acid (MSU) crystals (the etiological agent of gout) activate NLRP3, crystals of its analogue 
allopurinol do not. Therefore, although it has been shown that Imject® Alum is able to activate 
caspase-1 in vitro as much as licensed aluminium adjuvants do [321] the in vivo effects of a 
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formulation with different physico-chemical parameters are unpredictable and could partially 
account for the low level of immunogenicity seen in monkeys. Therefore the use of another 
adjuvant(s) may have resulted in a more robust and higher affinity antibody response. Inducing 
antibodies with greater affinity and higher titers, based on the knowledge from the isolated 
broadly NAb, would lead to more effective antibodies. The use of multiple adjuvants targeting 
different aspects of the innate system has led to higher antigen specific antibodies compared to 
the use of one adjuvant [322]. 
In addition to adjuvants as mentioned above, persistent antigen may play a role in the 
development of broadly neutralizing antibodies. This persistent antigen exposure has been 
implicated in the protective efficacy of the live attenuated vaccine [323-325], however the 
vaccine is not safe. DNA launched vectors are based on Flaviviruses, mainly the Venezuelan 
equine encephalitis (VEE) virus and the Sindbis virus, and the platforms allows the viral replicon 
(no structural genes) to be launched from a plasmid [326, 327]. The vector system retains the 
feature of high antigen presentation without the necessity of structural proteins [328]. These 
platforms are currently being investigated to eliminate induction of antibodies to the viral vectors 
structural proteins [329]. Our lab has partnered with Dr. Klimstra to test the DNA launch system 
with our HIV vaccine immunogens. The DNA launch plasmid is based on VEE and is under the 
cytomegalovirus immediate early promoter. An initial test of the launch vector showed that the 
vector expressed GFP at the injection site longer than vaccination with replicons of the same 
virus (unpublished data). It has been shown in literature that the use of VEE launch vector 
expressing an HIV envelope results in: 1) high level of protein, 2) type I IFN in vitro (induces 
Th-1 responses in mice), 3) effective prime to a protein boost, 4) increase humoral and cellular 
responses over VEE DNA only, 5) does not induce VEE replicon antibodies [327]. Preliminary 
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mouse studies with a Consensus M DNA launch vector resulted in a continuous increase in anti-
envelope antibody titer responses after the second vaccination Figure 23 (unpublished data).  A 
study using the DNA launch system expressing Consensus M will be used in a vaccine regimen 
to answer the question “Does persistent antigen presentation in a vaccine regimen increase the 
breadth and affinity of neutralizing antibodies elicited by the consensus envelope.”  
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Figure 23: DNA launch Consensus M Immunogenicity 
BalB/c mice were vaccinated at weeks 0,3 and 11. Sera were collected at weeks 3,5,11 and 13 post 
vaccination. The animal groups were 1) VEE DNA launch x2 /purified protein trimer boost (10µg) and 
VEE DNA launch prime/2x purified protein trimer boost (10µg). Total IgG responses to homologous 
envelope were determined via ELISA to consensus M. The endpoint titer is described on the y–axis and the 
weeks post vaccination on the x-axis. 
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The results in this project have provided additional evidence to support the use of 
consensus envelopes to increase the breadth of envelope specific humoral responses. This 
humoral binding breadth and limited neutralizing breadth did not result in protection from 
heterologous challenge.  Although vaccination with both vaccines elicited binding and 
neutralizing antibodies to the challenge envelope, only two animals in the Consensus M group 
had no detectable viral RNA in the presence of an “intact” immune system. Upon CD8 T cell 
depletion, detectable levels of viral RNA were observed in the plasma of one of the animals, 
referred to as M4. This depletion antibody used has only been reported to deplete CD8 T cells 
from blood and lymph nodes [330, 331]. Monkey M4 was not protected from viral infection as 
indicated by the emergence of virus after depletion.  The humoral response elicited by 
vaccination of monkey M4 resulted in a reduction in the virus inoculum. The antibody present 
together with the T cell response detected after challenge were sufficient to suppress viral loads 
to less than 50 RNA copies/ml of plasma. The other CD8 T cells depleted monkey (M1) had no 
detectable virus in its plasma even after CD8 T cell depletion. However, this monkey was 
exposed to virus sufficient to induce IFN-γ responses detectable by ELISPOT.  Therefore, it is 
likely that the animal was able to clear the virus from the blood. Complete viral clearance from 
other tissues, such as the gut, cannot be confirmed by CD8 T cell depletion as the antibody used 
has only been reported to deplete CD8 T cells in blood and lymph nodes. The other explanation 
of M1 protection is that the monkey received a reduced dose of infectious virus compared to the 
other animals upon challenge allowing the vaccine elicited response to be sufficient to prevent 
infection. 
These results bring into question how much antibody is needed to prevent infection. 
Experiments using low dose mucosal challenge models show that the level of antibody required 
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to protect from infection may be 10 fold lower than previously thought [332, 333]. Serum levels 
of antibodies required in these studies vary based on the epitope target and mechanism 
(Neutralizing or Fc-mediated effector) of the antibody.  An example of epitope target 
determining antibody level needed was observed when monkeys were protected with lower 
serum levels of the broadly neutralizing antibody 2G12, which recognize a cluster of high-
mannose glycans on gp120, then serum levels needed with b12 which binds to the CD4 epitope 
[332, 333]. This observation suggests that some antigenic epitopes induced more effective 
neutralizing antibodies than others. This difference in the level of antibodies needed to prevent 
infection being dependent on epitope target may explain the differences seen after challenge. In 
this study the level of total IgG was similar in all vaccinated animals, however not all animals 
were protected from infection (quality vs. quantity). While non-human primate data suggests a 
strong correlation between neutralizing antibodies (NAb) and protection, the Fc-mediated 
effector functions (ADCVI, ADCC) of antibodies have also been shown to have a role in 
protection [334, 335].  Finally, serum levels required for protection may vary depending on the 
viral challenge.  
Based on results from this project and information in the field, how much antibody is 
needed for protection is a delicate balance between the type of antibody present and the viral 
dose expose to the animal/ subject. In addition, if the antibodies present are not sufficient to 
prevent infection, the presence of an effective T cell response at the site of viral challenge is 
required to clear all infected cells before spread. Figure 24 below shows a model of how the 
balance between antibody and viral challenge resulted in multiple outcomes after challenge of 
the vaccinated animals in this study. 
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Figure 24: Model of the outcome of animals in this study after challenge. 
Monkey M1: was protected from challenge either due to sufficient antibodies present to protect from the viral dose 
given or the antibodies reduced the infectious dose enough to allow T cell present at the mucosal site to clear infected 
cells. Monkey M4: the antibodies and T cells present at the time of challenge was insufficient to prevent infection and 
spread of virus. However, the serum antibody and T cell responses were sufficient to reduce virus to undetectable 
serum levels. All other vaccinated animals did not have a sufficient antibody response to protect from viral challenge; 
either by preventing infection or reducing viral loads that would reduce viral transmission.  
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7.4 FUTURE STUDIES 
The next NHP vaccine study should consist of a vaccine regimen that includes an adjuvant 
system (more than one type of adjuvant) and the DNA launch vectors with not only Consensus 
M envelope but T cell antigens such as Tat and Gag. It was shown that the consensus envelope 
elicits binding breadth to multiple clades A, B, and C. Therefore, with better antibody affinity 
maturity the breadth and strength of the cross-clade neutralizing antibodies would increase. The 
addition of T cell antigens would elicit CD4+ T cell help that aid with the antibody maturity. 
Germinal center (GCs) formation is essential for the development of high-affinity antibody-
secreting plasma cells and long-lived memory B cells generation [336]; a process that is highly 
dependent on CD4 T-cell help [337]. Apart from CD4+T help the presence of effective CD8+T 
would be instrumental in the clearance of infected cells when sterilizing protection is not attained 
by the immune response elicited by vaccination. In terms of challenge, the multiple low dose 
challenges model should be used as it is more “real world” than the one high dose challenge. 
Furthermore, a more relevant SHIV should be used: the envelope SF162 was isolated from a 
chronic infection and, until recently, was the better of two SHIVs available for mucosal 
challenge. However, from late 2011 other groups have described additional SHIVs capable of 
infection at the mucosal surface with more relevant envelopes. These SHIVs have envelopes that 
were isolated early in infection and may be a better representation of viruses responsible for 
transmission [338-340].  
This project did not give rise to a broadly reactive HIV-1 vaccine that resulted in 
significant protection after SHIV challenge; however contributions have been made to the field. 
In summary, five consensus env trimers were designed and constructed and successfully 
expressed as trimeric envelope proteins. These synthetic envelopes retained functional and 
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antigenic epitopes, supporting previous work in the field reporting that synthetic consensus 
envelopes are similar to envelopes of isolated HIV viruses. Also, the five consensus Env trimers 
are now available as tools in mapping studies aimed at correlating presence of antigenic epitopes 
to induction of similar known antibodies and their role in protection from virus challenged.   
The Env trimers were also immunogenic in mice and monkeys. The antibodies elicited 
were able to bind to multiple envelopes from clades A, B, C and neutralize the challenge virus 
envelope SF162 via the in vitro neutralizing TZM-bl assay.  This was the first study that 
compared to group M vaccines directly: a single consensus M vaccine versus a polyvalent 
mixture of clade consensus envelopes. The mouse studies showed that all envelopes used in the 
polyvalent mixture were immunogenic on their own and this immunogenicity was not dampened 
when envelopes were placed into one vaccine. The results described in this dissertation have 
proven that a single group M envelope is able to induce similar breadth as a mixture of envelopes 
from multiple clades that group M comprises.  
Previous heterologous SHIV challenges reported in the literature have all been clade 
specific, most comprised of other HIV proteins mainly Gag and Tat and challenged with a 
multiple low dose infection model. In addition, the protection seen in those studies was not 
100%. This is the first study where a designed Group M Env only vaccine was used to protect 
from SHIV challenge. The protection from infection (M1) and reduced viral burden (M4) of 2 of 
4 animals vaccinated with the Con M Envgp140 shows a trend to protection of the single 
consensus envelope. This protection could be increased with a vaccine regimen that would result 
in a more robust and higher affinity antibody response. This finding is important as it supports 
the use of a group M vaccine being capable of providing some protection (prevention of 
infection or reduced viral burden) from virus challenge. 
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APPENDIX A 
CONSENSUS C VACCINE STUDY IN NHP 
Shown below is the data from a study performed at the Puerto Rico Primate facility to investigate 
the immunogenicity and efficacy of the consensus C envelope in the NHP model. The monkeys 
were given 2xDNA vaccinations (encoding gp140 consensus C trimers) 1 mg each ( 500µg IM& 
500µg ID) followed by 2xSHIV Con C VLP protein (500ug).VLP vaccination were given 
formulated with 125µg of CpG in a total volume of 500µl.  Eight weeks after final vaccination 
the animals were challenged with SHIV1157ipd3N4 repeated low dose 25TCID50. 
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Figure 25: Immunogenicity of Consensus C vaccine 
NHP were vaccinated at weeks 0, 4, 12 and 16 with blood collected 14 days after each vaccination. 
Vaccination consisted of 2xDNA vaccinations (encoding gp140 consensus C trimers) 1 mg each ( 500µg 
IM& 500µg ID) followed by 2xSHIV Con C VLP protein  (500µg) formulated with 125µg of CpG. Sera 
collected at week 18 were used to determine total IgG via ELISA for each vaccine group against consensus 
C vaccine. The endpoint titer is described on the y–axis and the animal groups described on the x-axis. 
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Figure 26: IFN-γ ELISPOT Responses after Vaccination 
INF-γ ELISPOTs were performed using monkey PBMCs collected week 18 (2 weeks after last vaccination) 
1x105 PBMCs were stimulated with 30µg of Gag peptide pools representing SIVmac239 or Env pools 
representing Consensus C (overlapping peptides, 15-mers with11 amino acid overlap NIH AIDS Research 
and Reference Reagent program. Spot forming units (SFU) per one million PBMCs are listed on the y-axis 
and animal groups listed on the x-axis. 
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Figure 27: Kinetics of Cross-binding Envelope responses 
Anti-Env IgG was detected in the serum samples (1:100 dilution) against a panel of primary Envgp120s from 
clades B ,and C via ELISA. Bar values represent the geometric mean titer (95% confidence interval) at an 
OD450. The OD450 values are displayed on the y-axis and animal groups are listed on the x-axis. A two-
way ANOVA with Bonferroni’s post-test was used to evaluate Statistical significance between the vaccines 
for each test antigen. A p-value of less than 0.05 was considered significant. 
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Table 6: Neutralizing Antibody responses to challenge virus envelope 
Neutralization of HIV SHIV1157ipd3N4 by serum collected post-challenge. Neutralizing antibodies to challenge 
virus after infection were detected sooner. Increase envelope breath seen in the vaccinated animals vs. 
mocks at week 2 post detectable virus 
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